immun
describ
process
deliv
care
packag
antigen
appropri
destin
vaccin
recipi
produc
desir
immun
respons
sens
immun
program
packag
deliveri
system
manag
flow
antigen
formul
vaccin
packag
differ
present
point
origin
vaccin
manufactur
point
consumpt
insid
antigenpres
cell
apc
vaccine
simpl
concept
deliv
antigen
packag
point
point
help
elucid
complex
logist
challeng
inher
preserv
packag
storag
transport
administr
vaccin
immun
one
power
tool
health
mani
current
vaccin
afford
access
accept
everyon
need
continu
sharpen
public
health
tool
need
achiev
full
potenti
immun
improv
health
advanc
come
form
better
vaccin
antigen
howev
signific
potenti
also
lie
improv
way
vaccin
packag
deliv
review
immun
packag
deliveri
process
recogn
critic
hurdl
bottleneck
barrier
vaccin
flow
first
step
toward
make
immun
program
effici
effect
manag
vaccin
flow
around
obstacl
daytoday
work
immun
program
often
requir
heroic
effort
chapter
briefli
describ
key
restrict
vaccin
flow
logist
term
complex
cost
human
resourc
requir
distribut
sourc
error
immun
process
review
new
technolog
variou
stage
develop
potenti
elimin
reduc
restrict
vaccin
flow
new
technolog
potenti
increas
capac
effici
immun
program
make
immun
safer
effect
afford
access
accept
everyon
four
key
point
antigen
packag
deliveri
system
point
origin
storag
distribut
point
point
care
poc
final
destin
point
recipi
point
origin
dozen
vaccin
manufactur
plant
antigen
produc
along
compon
formul
vaccin
vaccin
packag
multipl
layer
contain
storag
distribut
distribut
storag
point
form
network
thousand
site
vaccin
plant
nation
region
local
center
task
safe
store
transport
vaccin
poc
poc
million
hospit
clinic
health
post
home
compet
vaccin
inform
will
vaccine
safe
effect
vaccin
brought
togeth
vaccin
administr
final
destin
point
antigen
packag
deliveri
apc
insid
im
subcutan
sc
cutan
mucos
tissu
billion
peopl
benefit
immun
four
point
along
packag
deliveri
system
distinct
logist
challeng
antigen
packag
deliveri
system
origin
vaccin
manufactur
plant
formul
manufactur
packag
vaccin
well
describ
chapter
chapter
highlight
key
factor
relev
immun
logist
vaccin
manufactur
plant
highli
capit
multimilliondollar
facil
use
sophist
technolog
massproduc
billion
dose
vaccin
use
global
year
two
critic
vaccin
flow
logist
requir
start
plant
span
entir
immun
process
vaccin
individu
mainten
vaccin
puriti
b
mainten
vaccin
potenc
keep
within
prescrib
temperatur
rang
impos
signific
restrict
vaccin
flow
logist
maintain
puriti
vaccin
plant
environ
highli
regul
monitor
peopl
equip
materi
introduc
facil
precis
control
manner
expens
highspe
fill
equip
enabl
steril
packag
bulk
vaccin
specificdos
packag
low
cost
step
care
orchestr
even
minor
modif
procedur
materi
may
requir
approv
nation
regulatori
author
chang
process
impli
regulatori
consequ
signific
associ
econom
cost
see
chapter
almost
current
licens
vaccin
requir
storag
condit
includ
constant
mainten
sever
vaccin
requir
met
system
known
cold
chain
constrict
flow
vaccin
facil
deliveri
mechan
refriger
cold
pack
storag
capabl
vaccin
especi
includ
aluminum
adjuv
suscept
damag
freez
temperatur
other
especi
live
attenu
vaccin
suscept
loss
potenc
elev
temperatur
addit
stabil
case
addit
step
lyophil
freez
dri
vaccin
maintain
minimum
potenc
requir
storag
condit
throughout
list
shelf
life
break
cold
chain
detect
valuabl
vaccin
discard
undetect
cold
chain
failur
result
administr
ineffect
vaccin
vaccin
present
affect
flow
logist
contrast
mani
pharmaceut
current
licens
vaccin
administ
liquidsbi
needl
syring
inject
oral
deliveri
nasal
spray
vaccin
formul
packag
ship
liquid
singleor
multidos
vial
prefil
syring
other
first
formul
liquid
packag
vial
lyophil
enhanc
stabil
although
ship
dri
format
lyophil
vaccin
must
accompani
liquid
diluent
reconstitut
onsit
fill
administr
devic
vaccin
vaccin
distribut
key
logist
concept
easili
vaccin
transport
poc
administ
vaccin
recipi
cold
chain
requir
everi
level
storag
distribut
significantli
reduc
vaccin
distribut
gener
complex
difficulti
associ
cold
chain
manag
increas
distanc
manufactur
rel
easi
keep
larg
quantiti
vaccin
refriger
monitor
cold
room
vaccin
plant
larg
nation
region
storag
facil
economi
scale
reduc
per
dose
cost
storag
howev
maintain
refriger
storag
aroundtheclock
monitor
backup
energi
sourc
smaller
quantiti
vaccin
present
district
local
level
daunt
task
packag
ship
must
avoid
delay
could
allow
vaccin
temperatur
rise
transport
vaccin
cold
temperatur
end
cold
chain
transport
often
unrefriger
vehicl
requir
insul
box
cold
pack
significantli
increas
weight
expens
difficulti
vaccin
needl
syring
inject
requir
highli
skill
staff
combin
limit
staff
suppli
restrict
distribut
selfadminist
vaccin
could
significantli
increas
distribut
oral
typhoid
vaccin
approv
selfadministr
thermost
selfadminist
vaccin
distribut
regular
mail
system
selfadminist
conceptu
exampl
ideal
distribut
poc
set
three
essenti
compon
meet
vaccin
vaccin
vaccine
ideal
care
compet
vaccin
administ
safe
effect
vaccin
inform
will
vaccine
chapter
focus
logist
get
vaccin
safe
poc
technolog
vaccin
administr
get
vaccin
vaccine
poc
equal
import
complex
vaccin
process
increas
skill
level
requir
vaccin
increas
well
safe
inject
requir
highli
train
staff
oral
vaccin
deliveri
perform
minim
train
volunt
mani
pharmaceut
treatment
selfadminist
oral
typhoid
current
vaccin
approv
selfadministr
selfvaccinationen
vaccine
vaccinatorcould
overcom
substanti
logist
bottleneck
result
skill
vaccin
shortag
get
potenti
vaccine
poc
also
difficult
place
need
close
conveni
everyon
need
vaccin
feasibl
vaccine
home
may
conveni
poc
mani
mass
immun
campaign
lowresourc
set
conduct
housetohous
achiev
maximum
coverag
howev
logist
challeng
increas
rise
number
poc
distanc
distribut
point
vaccin
hesit
result
lack
confid
vaccin
health
system
complac
risk
vaccineprevent
diseas
inconveni
immun
anoth
limit
factor
get
potenti
vaccine
poc
multifacet
problem
must
address
mani
level
pain
associ
inject
needl
phobia
one
issu
may
caus
peopl
seek
vaccin
mani
adult
children
suffer
needl
phobia
needlefre
vaccin
deliveri
technolog
may
increas
accept
vaccin
vaccin
vaccin
deliveri
vaccin
administr
term
may
refer
act
transport
vaccin
across
skin
vaccine
cutan
sc
im
liquid
diluent
increas
volum
weight
vaccin
may
increas
ship
cost
requir
cold
chain
storag
capac
also
risk
spill
leakag
thu
lyophil
format
vaccin
liquid
diluent
slow
effici
vaccin
flow
three
basic
vaccin
present
scheme
prefil
deliveri
devic
liquid
vaccin
vial
ampul
lyophil
vaccin
vial
prefil
deliveri
devic
simplifi
logist
poc
minim
onsit
prepar
also
reduc
number
compon
ship
elimin
need
separ
suppli
chain
vaccin
diluent
administr
devic
reduc
fill
overag
requir
vial
ampul
howev
packag
vaccin
prefil
deliveri
devic
expens
larger
volum
devic
increas
space
need
cold
chain
storag
liquid
vaccin
packag
ship
vial
ampul
typic
cost
less
per
dose
occupi
less
cold
chain
space
prefil
vaccin
present
requir
fill
administr
devic
poc
increas
deliveri
complex
creat
opportun
error
withdraw
wrong
dose
amount
vial
contamin
vaccin
vaccin
vial
singleor
multidos
format
multidos
vial
typic
cost
less
per
dose
occupi
less
cold
chain
space
singledos
vial
howev
vaccin
wastag
may
increas
multidos
vial
vial
open
fewer
peopl
need
vaccin
dose
vial
vaccin
also
may
reluct
open
vial
one
two
peopl
need
vaccin
lead
miss
opportun
vaccin
peopl
repeat
entri
multidos
vial
time
laps
vaccin
withdraw
increas
risk
bacteri
fungal
overgrowth
subsequ
inject
contamin
vaccin
singledos
vial
avoid
problem
cost
per
dose
occupi
cold
chain
space
still
requir
onsit
fill
deliveri
devic
lyophil
vaccin
packag
singleor
multidos
vial
share
problem
liquid
vaccin
vial
reconstitut
step
need
lyophil
vaccin
add
complex
deliveri
creat
opportun
error
use
wrong
amount
diluent
wrong
diluent
challeng
reconstitut
includ
potenti
mismatch
amount
dri
vaccin
diluentwhich
often
ship
store
separ
vaccin
cold
chain
diluent
ambient
temperatureand
temperatur
differ
diluent
dri
vaccin
may
render
vaccin
ineffect
upon
reconstitut
inabl
overcom
challeng
present
multidos
liquid
vial
present
lyophil
present
result
failur
immun
vaccine
crosscontamin
infecti
pathogen
among
person
receiv
vaccin
advers
reaction
includ
local
abscess
toxic
shock
syndrom
even
death
although
rare
error
grave
consequ
may
significantli
undermin
public
confid
vaccin
recent
exampl
reconstitut
error
occur
syria
anesthet
agent
mistakenli
use
vaccin
diluent
result
infant
death
mani
hospit
complex
network
storag
ship
facil
manag
distribut
vaccin
dozen
manufactur
million
poc
challeng
associ
time
order
purchas
inventori
monitor
stagger
result
ongo
attempt
improv
immun
program
develop
softwar
assist
logist
higher
level
mucos
immun
major
challeng
mucos
vaccin
deliveri
antigen
target
tissu
much
less
consist
im
sc
vaccin
inject
mucos
vaccin
deposit
vaccin
intern
surfac
bodi
although
vaccin
insid
bodi
still
must
evad
varieti
defens
mechan
penetr
mucos
surfac
contact
target
tissu
mucu
flow
gastric
acid
mucos
antibodi
antimicrobi
substanc
continu
destroy
remov
substanc
mucos
surfac
result
mucos
vaccin
gener
requir
higher
dose
antigen
macrodeliveri
technolog
assur
tissu
contact
special
antigen
microdeliveri
packag
reach
apc
consist
vaccin
deliv
antigen
packag
person
receiv
vaccin
deliveri
complet
apc
intern
antigen
immun
involv
mimicri
vaccin
must
never
pathogen
must
caus
apc
respond
antigen
pathogen
one
first
principl
mimicri
antigen
packag
pathogens
free
antigen
solut
typic
ignor
immun
cell
howev
apc
readili
take
microparticl
packag
size
rang
pathogen
virus
bacteria
phagocytosi
endocytosi
microparticl
antigen
packag
like
assess
threaten
initi
immun
respons
molecular
antigen
packag
may
includ
adjuv
nonantigen
compon
design
trigger
modifi
immun
respons
adjuv
act
packag
warn
label
alert
activ
innat
immun
system
adjuv
creat
depot
effect
caus
antigen
packag
open
gradual
prolong
presenc
antigen
deliveri
site
anoth
molecular
antigen
packag
strategi
inclus
specif
cellular
address
label
typic
vaccin
macrodeliveri
system
place
molecular
antigen
packag
near
tissu
apc
resid
travers
vaccin
use
molecul
match
receptor
apc
dendrit
cell
cell
increas
likelihood
deliveri
specif
cell
mani
molecular
packag
strategi
antigen
deliveri
use
develop
describ
detail
chapter
chapter
exampl
describ
briefli
later
chapter
apc
receiv
antigen
packag
next
step
process
antigen
present
lymphocyt
initi
immun
respons
well
describ
chapter
prepar
emerg
includ
everi
nation
immun
program
plan
nation
program
develop
develop
countri
vari
degre
success
achiev
high
routin
vaccin
coverag
rate
strengthen
routin
system
key
step
emerg
immun
prepared
special
situat
highrisk
popul
increas
immun
logist
challeng
creat
need
rapid
deliveri
vaccin
vastli
increas
number
peopl
war
arm
conflict
interrupt
routin
vaccin
servic
displac
larg
popul
away
avail
servic
often
concentr
peopl
refuge
set
significantli
increas
risk
diseas
need
vaccin
natur
disast
earthquak
tsunami
hurrican
disrupt
local
infrastructur
includ
transport
electr
need
maintain
tissu
orific
contact
mucos
tissu
vaccin
deliveri
system
use
administr
inject
needl
syring
jet
injector
microarray
may
consid
macrodeliveri
system
contrast
vaccin
microdeliveri
system
molecular
antigen
packag
technolog
viral
vector
microparticl
viruslik
particl
vlp
help
transport
antigen
apc
administ
vaccine
current
vaccin
administ
needl
syring
inject
im
sc
intraderm
id
tissu
vaccin
deliv
mucos
oral
intranas
rout
vaccin
administr
method
devic
critic
aspect
immun
logist
mani
new
immun
technolog
describ
chapter
focu
vaccin
macrodeliveri
system
vaccin
inject
hypoderm
inject
needl
syring
date
back
centuri
predomin
vaccin
administr
method
shot
jab
often
consid
synonym
vaccin
mass
product
needl
syring
result
extrem
low
cost
devic
inject
breach
skin
stratum
corneum
protect
layer
dead
keratin
epitheli
cell
deposit
vaccin
direct
contact
underli
dermal
sc
muscl
tissu
im
sc
deliveri
vaccin
needl
syring
provid
highli
consist
dose
id
inject
dermal
layer
thin
precis
target
deposit
difficult
id
needl
inject
may
provid
less
consist
deliveri
target
tissu
overal
needl
syring
vaccin
produc
excel
immun
respons
extrem
safe
proper
procedur
follow
train
vaccin
howev
signific
logist
limit
inher
needl
syring
inject
high
level
skill
requir
safe
inject
limit
avail
vaccin
reus
contamin
syring
needl
common
develop
countri
lead
transmiss
bloodborn
diseas
hepat
hiv
inexpens
autodis
syring
needl
prevent
reus
mitig
problem
howev
autodis
devic
use
mani
develop
countri
risk
needlestick
injuri
healthcar
worker
remain
concern
increas
healthcar
cost
safeti
syring
includ
needlestick
protect
featur
describ
later
chapter
reduc
risk
needlestick
injuri
final
cost
complex
safe
dispos
sharp
medic
wast
stream
repres
major
logist
challeng
overcom
mani
difficulti
needl
syring
inject
multius
nozzl
jet
injector
munji
commonli
use
past
im
sc
inject
howev
repeat
use
jet
inject
nozzl
without
clean
patient
shown
risk
transmiss
bloodborn
pathogen
use
devic
discontinu
dispos
syring
jet
injector
dsji
elimin
contamin
problem
discuss
detail
later
chapter
mucos
vaccin
addit
vaccin
inject
current
macrodeliveri
method
includ
mucos
vaccin
via
oral
ingest
nasal
spray
deliveri
method
share
advantag
needl
free
present
possibl
simpl
administr
method
mucos
vaccin
mimic
rout
entri
portal
mucos
tissu
mani
infecti
agent
typic
provid
syring
inject
needlefre
vaccin
could
administ
minim
train
staff
volunt
could
selfadminist
would
significantli
increas
vaccin
deliveri
capac
third
import
logist
factor
immun
lmic
sharp
safeti
needlestick
injuri
common
howev
unlik
highincom
countri
needlestick
protect
devic
prophylaxi
prevent
bloodborn
diseas
transmiss
follow
injuri
often
avail
lowresourc
set
cost
safe
dispos
use
needl
requir
expens
biowast
dispos
infrastructur
alway
present
countri
use
needl
harvest
common
wast
stream
repackag
unsuspect
reus
present
high
risk
transmiss
bloodborn
pathogen
long
run
thermost
needlefre
vaccin
could
significantli
reduc
logist
hurdl
vaccin
deliveri
develop
countri
extend
benefit
immun
peopl
short
term
intermedi
technolog
develop
improv
cold
chain
ship
storag
provid
needlestick
injuri
protect
unit
statesus
exampl
develop
countryha
rel
strong
immun
program
infrastructur
reflect
high
vaccin
coverag
rate
except
certain
commun
vaccin
hesit
parent
led
histor
low
coverag
rate
unit
state
poc
includ
doctor
offic
health
clinic
within
last
sever
year
pharmaci
howev
emerg
new
vaccin
poc
may
establishedsuch
sport
arena
school
convent
center
nontradit
locationsto
allow
mass
vaccin
reach
larg
popul
rapidli
atrisk
individu
key
consider
includ
children
pregnant
women
peopl
disabl
elderli
among
group
event
pandem
bioterror
event
local
region
even
nation
healthcar
resourc
infrastructur
may
overwhelm
immun
logist
perspect
key
factor
includ
ensur
vaccin
suppli
distribut
establish
access
poc
larg
number
peopl
provid
suffici
skill
vaccin
meet
vaccin
demand
us
strateg
nation
stockpil
maintain
suppli
key
vaccin
cold
chain
logist
may
becom
issu
emerg
set
collater
damag
power
infrastructur
natur
disast
hurrican
massiv
increas
vaccin
volum
overwhelm
local
cold
chain
capac
contrast
mani
develop
countri
unit
state
littl
recent
experi
mass
vaccin
campaign
pandem
set
bioterror
event
involv
infecti
agent
gather
mass
peopl
central
locat
vaccin
may
repres
increas
risk
transmiss
diseas
thu
discret
method
vaccin
distribut
may
prefer
major
immun
logist
challeng
vaccin
flow
includ
follow
distribut
multicompon
product
puriti
steril
requir
cold
chain
requir
avail
highli
skill
vaccin
onsit
fill
reconstitut
needl
safeti
issu
transfer
antigen
apc
technolog
describ
chapter
address
mani
challeng
overal
practic
ideal
vaccin
cold
chain
vaccin
suppli
emerg
situat
expand
demand
skill
vaccin
often
suppli
diminish
vaccin
person
affect
emerg
pull
emerg
duti
reduc
logist
barrier
routin
vaccin
deliveri
critic
assur
barrier
insurmount
emerg
situat
lowand
middleincom
countri
lmic
nation
immun
program
provid
vaccin
recommend
world
health
organ
follow
diseas
diphtheria
hepat
b
haemophilu
influenza
type
b
hib
measl
pertussi
polioviru
tetanu
tuberculosi
routin
immun
vaccin
administ
health
post
clinic
fix
post
commun
mobil
outreach
daili
weekli
monthli
schedul
mani
countri
also
provid
vaccin
pneumococc
diseas
rotaviru
pathogen
supplement
immun
activ
includ
mass
campaign
fix
post
often
includ
extra
post
mobil
outreach
housetohous
campaign
three
critic
immun
deliveri
hurdl
lmic
cold
chain
requir
need
skill
vaccin
sharp
safeti
cold
chain
storag
requir
especi
challeng
countri
high
ambient
temperatur
unreli
access
electr
keep
vaccin
tether
refriger
limit
capac
distribut
everyon
need
transport
remot
locat
requir
cold
packag
equip
mani
time
larger
heavier
vaccin
cold
chain
studi
vietnam
commun
health
center
assess
refriger
limit
vaccin
day
vaccin
transport
district
facil
cold
box
health
center
immedi
use
mani
countri
cold
chain
equip
antiqu
storag
capac
stretch
limit
restrict
implement
new
vaccin
elimin
surg
capac
massvaccin
storag
case
epidem
mani
immun
program
purchas
mainten
cold
chain
equip
consum
signific
portion
immun
budget
one
studi
estim
cold
chain
equip
overhead
cost
would
account
billion
need
nonvaccin
immun
program
cost
lowand
lowermiddleincom
countri
vaccin
may
thermost
allow
manag
outsid
cold
chain
limit
period
time
exampl
major
reason
success
menafrivac
campaign
africa
relax
cold
chain
requir
number
countri
last
mile
deliveri
countri
control
temperatur
chain
implement
allow
vaccin
ship
store
ambient
temperatur
day
addit
increas
access
difficulttoreach
area
model
studi
estim
use
control
temperatur
chain
could
potenti
reduc
cold
chain
associ
logist
cost
addit
studi
base
field
implement
requir
research
thermost
vaccin
may
enabl
use
control
temperatur
chain
simplifi
logist
last
difficult
mile
deliveri
improv
vaccin
access
remot
area
potenti
reduc
cost
second
hurdl
immun
program
mani
lmicsand
often
ratelimit
factori
shortag
skill
vaccin
global
shortag
healthcar
worker
safe
effect
vaccin
requir
highli
skill
worker
mani
vaccin
particularli
needl
urg
vaccin
manufactur
reduc
elimin
thimeros
vaccin
precautionari
measur
current
unit
state
routin
vaccin
thimerosalfre
level
less
equal
mercuri
per
dose
two
preserv
prequalifi
vaccin
use
inactiv
polioviru
vaccin
ipv
phenol
use
inactiv
typhoid
vaccin
mani
industri
countri
unit
state
switch
singledos
vial
use
routin
immun
thimeros
use
vial
access
howev
multidos
vial
format
season
influenza
vaccin
vaccin
epidem
pandem
respons
preserv
thimeros
continu
use
furthermor
mani
vaccin
use
lmic
still
contain
thimeros
includ
diphtheria
tetanu
pertussi
hepat
b
hib
influenza
meningococc
vaccin
lmic
use
singledos
vial
present
limit
vaccin
manufactur
product
capac
increas
cold
chain
volum
cost
mani
countri
absorb
extend
exposur
elev
freez
temperaturesthos
temperatur
outsid
recommend
rang
normal
damag
vaccin
heat
denatur
otherwis
alter
protein
tertiari
structur
may
reduc
viabil
liveattenu
vaccin
case
polysaccharid
conjug
vaccin
result
increas
rate
hydrolysi
polysaccharid
protein
vaccin
formul
format
ice
crystal
result
freez
damag
antigen
freez
vaccin
contain
aluminum
adjuv
reduc
potenc
agglomer
adjuv
thermost
resist
high
ambient
temperatur
freez
could
reduc
potenc
loss
posit
impact
vaccin
efficaci
could
also
allow
remov
vaccin
cold
chain
reduc
cost
lead
increas
coverag
allow
flexibl
time
reach
remot
popul
thermost
product
could
dri
cake
similar
lyophil
vaccin
would
requir
reconstitut
prior
inject
dri
formul
could
incorpor
unitdos
dryformat
deliveri
system
microarray
patch
dri
powder
aerosol
respiratori
administr
see
cutan
vaccin
mucos
vaccin
later
format
would
combin
benefit
needl
free
thu
simpl
administ
selfadminist
would
requir
refriger
reconstitut
protect
high
ambient
temperatur
enhanc
thermost
liquid
formul
vaccin
achiev
select
buffer
agent
use
excipi
vaccin
formul
ingredi
antigen
stabil
formul
exampl
includ
nonreduc
sugar
nonion
surfact
polym
protein
stabil
excipi
stabil
enhanc
protect
shift
ph
decreas
antigen
loss
result
surfac
adsorpt
aggreg
prevent
reduc
proteintoprotein
interact
freez
protect
propylen
glycol
polyethylen
glycol
glycerol
use
protect
aluminumadjuv
vaccin
freez
variou
concentr
propylen
glycol
prevent
vaccin
freez
loss
potenc
prevent
destruct
particl
aggreg
physic
freez
occur
dryformat
deliveri
altern
process
lyophil
vaccin
dri
remov
water
molecul
vaccin
deliveri
system
would
thermost
vaccin
prefil
unit
dose
needlefre
deliveri
minim
wast
vaccin
would
optim
ship
even
mail
case
would
selfadminist
administ
minim
train
personnel
molecular
antigen
packag
would
ensur
safe
deliveri
antigen
apc
induct
immun
respons
minim
advers
reaction
maintain
integr
potenc
safeti
vaccin
point
origin
vaccin
manufactur
point
prepar
use
requir
attent
vaccin
formul
packag
primari
secondari
tertiari
contain
reconstitut
develop
vaccin
formul
includ
chemic
physic
character
antigen
potenc
assay
lot
releas
demonstr
stabil
preclin
clinic
evalu
optim
administr
rout
includ
potenti
use
adjuv
formul
stabil
develop
current
liveattenu
vaccin
formul
adjuv
nonrepl
vaccin
includ
inactiv
virus
bacteria
vlp
carbohydr
antigen
purifi
recombin
subunit
protein
antigen
typic
present
liquid
solut
suspens
usual
contain
adjuv
induc
desir
immun
respons
vaccin
formul
consist
antigen
well
support
ingredi
call
excipi
excipi
includ
preserv
prevent
contamin
adjuv
enhanc
potenc
care
develop
formul
also
increas
thermost
vaccin
avoid
damag
antigen
due
freez
high
temperatur
liveattenu
vaccin
often
lyophil
freez
stabl
tend
heat
sensit
longterm
storag
month
year
cold
chain
immedi
reconstitut
nonrepl
vaccin
stabl
high
temperatur
compar
liveattenu
vaccin
also
damag
freez
particularli
includ
aluminum
adjuv
preserv
thimeros
organ
mercuri
preserv
approxim
weight
form
ethyl
mercuri
use
inactiv
vaccin
multidos
vial
format
prevent
microbi
growth
open
partial
use
vial
also
use
vaccin
manufactur
process
inactiv
agent
thimeros
intend
kill
prevent
growth
broad
spectrum
pathogen
bacteria
fungi
safeti
thimeros
evalu
global
advisori
committe
vaccin
safeti
well
nationallevel
expert
group
regulatori
bodi
european
agenc
evalu
medicin
product
american
academi
pediatr
us
food
drug
administr
fda
evalu
conclud
given
short
biolog
halflif
ethyl
mercurywhich
excret
via
gut
accumul
bodyevid
longterm
toxic
effect
demonstr
howev
us
public
health
servic
vaccin
must
prequalifi
purchas
un
agenc
requir
vaccin
qualiti
safeti
efficaci
includ
prequalif
process
well
complianc
requir
manufactur
specif
packag
present
prequalif
provid
assur
vaccin
use
nation
immun
program
safe
effect
meet
qualiti
standard
vaccin
present
packag
advisori
group
vppag
unit
nation
children
fund
unicef
led
forum
public
sector
industri
discuss
provid
advic
vaccin
present
packag
vppag
develop
gener
prefer
product
profil
vaccin
lmic
use
recommend
readytous
present
requir
mix
ie
reconstitut
format
reduc
number
user
step
potenti
error
vaccin
formul
improv
heat
freez
stabil
also
recommend
provid
higher
temperatur
storag
target
threshold
potenti
use
beyond
cold
chain
prefil
syring
inject
system
reduc
volum
requir
cold
chain
incorpor
autodis
featur
prevent
reus
design
design
compact
prefil
autodis
inject
devic
cpad
gener
prefer
product
profil
also
includ
vaccin
vial
dimension
recommend
conform
iso
effici
size
cold
chain
vial
label
includ
vaccin
vial
monitor
per
unicef
recommend
consist
temperaturesensit
materi
serv
visual
indic
cumul
heat
exposur
label
also
includ
standard
product
date
lot
inform
among
requir
unit
dose
versu
multidos
format
multidos
present
common
lmic
result
lower
cost
reduc
perdos
volum
compar
singledos
present
industri
highincom
countri
less
vaccinepric
sensit
switch
singledos
present
adult
childhood
vaccin
shift
singl
dose
acceler
public
concern
regard
thimeros
healthcar
provid
prefer
singledos
present
includ
prefil
syring
increas
awar
inject
safeti
unit
state
awar
safeti
issu
came
respons
needlestick
safeti
prevent
act
subsequ
revis
occup
safeti
health
administr
osha
bloodborn
pathogen
standard
led
requir
workplac
report
mainten
log
needlestick
injuri
well
broader
implement
engin
safeti
featur
reduc
prevent
risk
needlestick
injuri
use
singledos
small
multidos
present
also
increas
lmic
part
higher
cost
vaccin
wastag
newer
vaccin
use
preserv
multidos
vial
critic
import
vaccin
use
one
immun
session
repeat
access
vial
septum
well
storag
session
present
potenti
contamin
risk
pathogen
ingress
multidos
vial
polici
permit
open
vial
vaccin
preserv
handl
specif
condit
use
day
first
dose
withdrawn
guidelin
consist
us
recommend
also
requir
open
vial
discard
day
except
differ
manufactur
requir
product
label
may
specifi
altern
number
day
polici
appli
liquid
vaccin
contain
preserv
lyophil
live
attenu
vaccinessuch
measlescontain
vaccin
bacillu
bcg
yellow
fever
vaccinesgener
contain
preserv
must
discard
maximum
hour
suspens
includ
spray
dri
sprayfreez
dri
sfd
vacuumfoam
dri
supercrit
fluid
dri
process
evalu
increas
vaccin
thermost
research
aluminumhydroxideadjuv
hepat
b
surfac
antigen
hbsag
human
papillomaviru
hpv
vaccin
aluminumphosphateadjuv
diphtheria
tetanu
toxoid
conduct
use
altern
freezedri
process
studi
typic
found
aluminum
coagul
difficulti
reconstitut
lyophil
adjuv
vaccin
although
addit
excipi
thin
film
freezedri
process
may
provid
freez
protect
sfd
method
produc
homogen
suspens
indic
feasibl
approach
aluminumadjuv
vaccin
evalu
sfd
hbsag
without
aluminum
combin
inulin
dextran
trehalos
stabil
demonstr
enhanc
thermost
howev
preclin
immunogen
studi
formul
demonstr
immunoglobulin
ig
g
immun
respons
lower
respons
aluminumadjuv
hbsag
sfd
also
assess
mening
measl
vaccin
addit
altern
deliveri
packag
method
dri
powder
inhal
microarray
patch
biodegrad
implant
integr
reconstitut
technolog
discuss
later
chapter
current
develop
use
biolog
pharmaceut
could
adapt
vaccin
primari
excipi
includ
nonreduc
sugar
trehalos
sucros
high
glasstransit
temperatur
exhibit
glass
amorph
solid
form
instead
crystal
excipi
dri
contribut
vaccin
stabil
vaccin
packag
collect
compon
surround
vaccin
protect
integr
potencyst
shelf
life
product
suppli
chain
poc
vaccin
packag
typic
divid
three
categori
primari
secondari
tertiari
primari
packag
protect
light
oxygen
moistur
vapor
ingress
must
allow
ph
shift
could
affect
vaccin
stabil
antigen
bind
materi
contain
could
reduc
avail
dose
packag
also
provid
inform
identif
content
label
identifi
product
must
integr
packag
affix
primari
contain
nest
togeth
secondari
packag
larger
contain
box
carton
provid
tertiari
packag
vial
ampoul
vaccin
diluent
primari
packag
ampoul
vial
prefil
syring
prefil
oral
dispens
come
direct
contact
vaccin
product
diluent
may
affect
vaccin
formul
issu
guidelin
cover
vaccin
formul
present
label
packag
ensur
vaccin
submit
prequalif
optim
address
lmic
need
guidelin
includ
mandatori
critic
uniqu
innov
prefer
characterist
mandatori
critic
characterist
must
met
achiev
prequalif
case
critic
characterist
deviat
defin
valu
may
allow
take
account
public
health
need
uniqu
innov
characterist
may
vaccin
specif
review
prefer
characterist
requir
repres
buyer
prefer
procur
agenc
nation
immun
program
syring
typic
expens
glass
exampl
includ
bd
sterifil
scf
schott
toppac
gerresheim
clearject
baxter
clearshot
west
daikyo
crystal
zenith
readytous
siliconefre
syring
cyclic
olefin
copolym
cyclic
olefin
polym
also
use
vial
exampl
asept
technolog
inc
atclos
vial
compos
cyclic
olefin
copolym
see
fig
valid
use
glaxosmithklin
synflorix
pneumococc
vaccin
approv
european
medicin
agenc
compact
prefil
autodis
devic
cpad
prefil
singledos
inject
system
compar
prefil
syring
autodis
featur
prevent
reus
like
prefil
syring
cpad
provid
accur
dose
fast
inject
prepar
quick
deliveri
time
readi
use
addit
typic
smaller
standard
syring
bring
logist
benefit
decreas
volum
weight
bd
uniject
inject
system
see
fig
cpad
technolog
small
reservoir
prefil
vaccin
pharmaceut
four
main
compon
reservoir
port
needl
assembl
needl
shield
reservoir
threelay
lamin
film
linear
lowdens
polyethylen
contact
contain
fluid
port
valv
contact
fluid
reservoir
also
construct
lowdens
polyethylen
needl
assembl
connect
port
consist
polystyren
hub
steel
needl
pp
needl
shield
remov
needl
administr
typic
foillamin
secondari
pouch
maintain
stabil
materi
uniject
unit
crucel
develop
novel
hybrid
secondari
packag
uniject
system
store
fill
devic
needleless
version
uniject
platform
design
uniject
dp
also
develop
bd
oral
deliveri
commerci
avail
deliv
prefil
dose
remov
needl
shield
insert
needl
plastic
reservoir
uniject
system
squeez
thumb
finger
uniject
system
avail
four
dosevolum
size
ml
avail
variou
needl
gaug
length
rang
gaug
needl
length
inch
sc
im
inject
contain
provid
steril
readytofil
reel
steril
reel
load
onto
custom
fill
machin
contain
fill
heat
seal
kept
reel
throughout
process
either
accumul
reel
form
transfer
steril
area
final
packag
hepat
b
tetanu
toxoid
vaccin
made
pt
bio
farma
indonesia
whoprequalifi
uniject
format
crucel
develop
new
present
quinvaxem
fulli
liquid
pentaval
vaccin
uniject
prequalifi
commerci
timeandmot
studi
kenya
compar
averag
time
health
worker
prepar
inject
dose
pentaval
vaccin
five
differ
present
found
prefil
uniject
system
faster
deliv
fillonsit
present
singledos
multidos
vial
liquid
lyophil
novel
primari
contain
technolog
blowfills
bf
ampoul
plastic
primari
contain
manufactur
polyethylen
pp
use
varieti
pharmaceut
see
fig
contain
extrud
blown
fill
seal
autom
continu
process
although
ampoul
yet
approv
vaccin
evalu
medimmun
live
attenu
influenza
vaccin
laiv
evalu
rotaviru
vaccin
manufactur
parenter
deliveri
luer
interfac
incorpor
neck
ampoul
allow
connect
luertip
needl
needl
syring
also
simpli
withdraw
dose
standard
bf
ampoul
reconstitut
per
multidos
vial
polici
vaccin
wastag
concern
healthcar
worker
hesit
reconstitut
multidos
vial
insuffici
number
peopl
avail
vaccin
preservativefre
multidos
primari
packag
medinstil
inc
usbas
firm
develop
primari
packag
pharmaceut
fill
dispens
technolog
call
intact
may
reduc
elimin
need
preserv
multidos
vaccin
vial
technolog
design
reduc
risk
contamin
fill
dispens
primari
contain
maintain
steril
fill
process
closedsystem
valv
use
fill
needl
prevent
contamin
allow
steril
fill
nonasept
facil
addit
intact
design
incorpor
dispens
port
medinstil
primari
contain
valv
allow
multipl
withdraw
contain
maintain
steril
content
even
presenc
extern
contamin
multidos
vial
fig
pouch
design
undergo
evalu
pharmaceut
vaccin
prefil
syring
prefil
syring
repres
fulli
integr
vaccin
present
multipl
studi
compar
prefil
syring
standard
vial
present
demonstr
increas
effici
improv
vaccin
throughput
packag
format
exampl
studi
us
nurs
prepar
deliv
influenza
vaccin
report
time
necessari
provid
inject
second
prefil
syring
compar
second
multidos
vial
increas
effici
possibl
prefil
syring
parenter
nonparenter
administr
oralnas
could
greatli
enhanc
pandemicepidem
outbreak
respons
capac
glass
prefil
syring
glass
prefil
syring
manufactur
type
borosil
glass
high
chemic
resist
low
alkali
content
barrier
properti
appropri
longterm
storag
vaccin
pharmaceut
lead
exampl
becton
dickinson
compani
bd
hypak
scf
steril
clean
readi
fill
glass
prefil
syring
use
wide
unit
state
europ
see
fig
design
come
differ
model
includ
fixedneedl
luer
slip
luerlok
varieti
manufactur
includ
gerresheim
schott
nuova
ompi
nipro
catal
glass
use
decad
varieti
primari
contain
prefil
syring
vial
cartridg
problem
associ
use
includ
possibl
crack
breakag
plastic
prefil
syring
variou
plastic
materi
use
altern
glass
prefil
syring
primari
contain
technolog
plastic
syring
inject
mold
allow
tighter
dimension
toler
abil
gener
altern
geometri
plastic
prefil
syring
lighter
weight
resist
breakag
glass
product
fillfinish
ship
programmat
use
polypropylen
pp
polym
use
standardand
largevolum
prefil
syring
ml
vial
cyclic
olefin
copolym
cyclic
olefin
polym
cop
highli
transpar
polym
use
increasingli
prefil
syring
compar
pp
cyclic
olefin
copolym
cyclic
olefin
polym
lower
water
vapor
oxygen
permeabl
allow
longterm
storag
vaccin
demonstr
biocompat
resist
heat
compat
variou
termin
steril
process
select
glass
plastic
determin
formul
stabil
requir
pharmaceut
need
patientus
requir
plastic
prefil
tertiari
packag
includ
carton
case
enclos
multipl
secondari
packag
unit
insul
ship
box
intern
wall
polystyren
isocyanur
panel
polyurethan
foam
also
maintain
cold
chain
temperatur
prevent
shift
shipment
pallet
use
intern
shipment
contain
gener
specif
design
export
packag
ship
contain
wherea
put
categori
tertiari
packag
vppag
secondari
packag
recommend
includ
minim
weight
volum
need
incountri
repackag
distribut
cold
chain
specif
vial
array
rectangular
number
vial
pack
also
recommend
tertiari
packag
recommend
also
includ
minim
dimens
well
limit
need
repackag
vial
multipl
easier
inventori
control
weight
width
dimens
recommend
also
includ
refer
iso
pallet
size
label
recommend
also
includ
use
bar
code
conform
standard
materi
use
packag
primari
secondari
tertiari
minim
environment
impact
environment
friendli
secondari
carton
tertiari
ship
contain
numer
compani
develop
insul
product
replac
polystyren
green
cell
foam
technolog
biodegrad
starchbas
polym
break
within
four
week
dissolv
water
inciner
burn
cleanli
fig
maintain
temperatur
hour
ecov
develop
compost
plastic
deriv
agricultur
byproduct
mushroom
mycelium
wool
packag
use
renew
compost
materi
thermal
insul
coldpack
airlin
inflat
insul
liner
ship
flat
empti
space
save
deflat
landfil
dispos
placon
plastic
polyethylen
terephthal
secondari
packag
compos
least
postconsum
content
softbox
develop
new
thermal
insul
foam
recycl
materi
increas
thermal
effici
compar
styrofoam
softbox
maintain
cold
chain
half
world
top
pharmaceut
compani
credo
contain
pelican
biotherm
use
influenza
vaccin
temperaturesensit
drug
see
fig
repeat
flu
vaccin
shipment
altern
logisticsdistribut
model
use
success
demonstr
technolog
contain
reus
could
provid
reduc
environment
impact
dispos
burden
program
level
sonoco
thermosaf
greenbox
anoth
reusabl
contain
technolog
compos
biodegrad
biobas
materi
plantbas
phasechang
materi
allow
cold
chain
temperatur
mainten
day
phasechang
materi
recondit
use
repeatedli
replac
need
refriger
approxim
repeat
use
demonstr
thermal
manag
properti
materi
ship
vaccin
lyophil
form
advantag
improv
thermost
reconstitut
introduc
error
note
earlier
use
wrong
diluent
reconstitut
diluent
withdrawn
contain
typic
needl
syring
inject
primari
vaccin
contain
mix
reconstitut
vaccin
withdrawn
vaccin
contain
administr
vaccin
current
avail
lyophil
form
includ
yellow
fever
vial
integr
septum
catal
advasept
vial
technolog
see
fig
rommelag
weiler
engin
brevetti
angela
lead
exampl
bf
machin
manufactur
brevetti
angela
rommelag
bf
system
integr
needl
incorpor
form
process
see
fig
plastic
tube
inject
mold
extrud
develop
primarili
oral
administr
contain
manufactur
termin
steril
ship
pharmaceut
manufactur
fill
heat
seal
exampl
rexam
dispens
tube
use
glaxosmithklin
rotarix
vaccin
lameplast
tube
use
merck
rotateq
vaccin
see
fig
fund
bill
melinda
gate
foundat
path
collabor
rommelag
develop
multimonodos
bf
contain
design
target
rotaviru
vaccin
deliveri
design
individu
contain
conjoin
share
tab
one
contain
separ
tab
render
open
must
use
deliv
vaccin
attribut
provid
key
advantag
compar
singledos
present
includ
cold
chain
volum
reduct
potenti
cost
save
see
fig
safeti
syring
needlestick
safeti
prevent
act
sign
law
led
standard
use
syring
engin
safeti
featur
vaccin
drug
deliveri
unit
state
one
studi
found
begin
result
drop
onethird
needlestick
injurieswith
approxim
annual
reduct
cost
save
million
million
howev
cochran
review
conclud
clear
evid
benefit
use
devic
despit
increas
cost
achiev
prequalif
vaccin
prefil
syring
requir
autodis
reuseprevent
featur
autodis
syring
attach
needl
method
prevent
reus
needl
syring
deliveri
fix
dose
reuseprevent
featur
syring
allow
variabl
dose
necessari
volum
diluent
transfer
vaccin
reconstitut
recommend
autodis
syring
syring
reuseprevent
featur
vaccin
administr
also
recommend
syring
sharp
injuri
protect
sip
featur
immun
sharp
injuri
protect
featur
cover
shield
retract
needl
syring
barrel
prevent
needlestick
use
dispos
multipl
selfshield
needl
technolog
introduc
reduc
risk
needlestick
injuri
current
cost
syring
limit
use
lmic
unifil
safeti
syring
unilif
medic
solut
reuseprevent
featur
retract
needl
deliveri
develop
includ
tiptop
safeti
syring
credenc
medsystem
prefil
syringecompat
sharp
injuri
protect
design
incorpor
syring
fill
merck
gardasil
hpv
vaccin
deliv
singledos
prefil
syring
ultrasaf
needl
guard
clipon
prefil
syring
safeti
mechan
also
includ
bd
preventi
west
clip
nject
special
health
product
intern
luproloc
secondari
packag
carton
tray
foil
pouch
hold
one
primari
contain
vial
prefil
syring
vaccin
packag
gener
repres
volum
calcul
cold
chain
storag
requir
secondari
packag
import
vaccin
stabil
exampl
foil
pouch
protect
polymerbas
primari
contain
uniject
system
water
vapor
loss
oxygen
ingress
light
vaccin
packag
reconstitut
technolog
landaal
green
cell
foam
biodegrad
polym
easili
dispos
dissolv
inciner
b
credo
contain
pelican
biotherm
repeatedli
reus
use
influenza
vaccin
temperaturesensit
drug
c
vetter
lyoject
syring
dualchamb
technolog
simplifi
reconstitut
duoject
vaccjet
cartridgebas
technolog
use
dualsid
needl
parenter
inject
e
neopac
flexim
easymix
use
frangibl
seal
separ
wet
dri
compart
pressur
squeez
one
end
break
seal
allow
reconstitut
f
aktivax
arch
design
use
blister
frangibl
seal
separ
dri
vaccin
diluent
prior
mix
g
eulysi
sv
vialbas
design
compart
separ
dri
powderlyophil
pharmaceut
diluent
pierc
piston
cap
allow
mix
h
hydri
nova
laboratori
distal
hubattach
prefil
diluent
syring
fill
lyophil
pharmaceut
sugar
glass
base
membran
reconstitut
occur
upon
expel
diluent
syring
compart
process
deliveri
anoth
manufactur
unilif
develop
dualchamb
syring
ezmix
genesi
incorpor
retract
needl
featur
cartridgebas
reconstitut
technolog
requir
incorpor
separ
novel
deliveri
devic
duoject
vaccject
technolog
design
singleus
deliveri
use
retract
needl
allow
cartridg
access
see
fig
reconstitutioncap
version
vaccject
develop
featur
allow
diluent
transfer
one
cartridg
cartridg
contain
lyophil
vaccin
drug
frangibl
sealbas
technolog
tube
pouch
blister
pack
altern
syring
cartridg
reconstitut
use
tube
pouch
blister
pack
frangibl
seal
separ
diluent
lyophil
dri
powder
vaccin
frangibl
refer
properti
break
fragment
deform
otherwis
place
suffici
stress
frangibl
seal
ruptur
upon
applic
pressur
allow
diluent
mix
pharmaceut
materi
use
seal
must
compat
heat
seal
includ
pp
polyest
coextrud
lamin
water
vapor
oxygen
transfer
rate
relat
differ
materi
must
consid
affect
product
stabil
aluminum
dualchamb
foil
pouch
use
oral
cholera
vaccin
orochol
crucel
formerli
berna
biotech
howev
product
longer
avail
frangibl
seal
pouch
use
nonpharmaceut
pointofus
compon
mix
exampl
commerci
avail
tube
frangibl
seal
neopac
flexim
easymix
twocompart
coextrud
polymerbas
tube
seal
separ
two
compart
contain
dri
liquid
two
liquid
compon
see
fig
reconstitut
occur
user
appli
pressur
ruptur
seal
compart
nozzl
oral
deliveri
avail
luer
interfac
allow
fill
syring
attach
luerfit
needl
pharmaceut
must
dri
format
dispens
tube
seal
use
technolog
vaccin
may
requir
shift
dri
techniqu
lyophil
eg
sfd
aktivax
arch
asept
reconstitut
cartridg
hybrid
polym
prefil
syring
incorpor
flexibl
packag
solid
back
see
fig
arch
packag
accommod
one
constitu
pharmaceut
store
adjac
highbarri
compart
separ
frangibl
seal
broken
depress
thumb
reconstitut
prior
inject
mix
pharmaceut
drawn
attach
syring
inject
arch
syring
incorpor
stake
needl
luer
interfac
technolog
discuss
use
flexibl
packag
may
requir
updat
vaccin
lyophil
dri
techniqu
integr
needlebas
design
use
arch
featuresth
immunojectalso
develop
aktivax
design
twocompart
blister
attach
needl
foldabl
plastic
back
plastic
back
shield
needl
use
allow
compress
blister
compart
ruptur
frangibl
seal
reconstitut
reconstitut
integr
needl
allow
parenter
administr
refold
plastic
back
disabl
cover
needl
technolog
character
integr
primari
contain
reconstitut
featur
dual
chamber
without
integr
deliveri
featur
parenter
measl
rubella
varicella
measlescontain
combin
vaccin
measlesrubella
measlesmumpsrubella
mmr
measlesmumpsrubellavaricella
bcg
hib
standalon
combin
vaccin
rabi
rotaviru
japanes
enceph
meningococcu
laiv
vaccin
develop
includ
cholera
dengu
enterotoxigen
escherichia
coli
influenza
tuberculosi
rotaviru
like
avail
format
requir
reconstitut
prepar
deliveri
reconstitut
vaccin
requir
vaccin
time
prepar
deliveri
liquid
vaccin
timemot
studi
conduct
kenya
compar
amount
time
requir
vaccin
prepar
deliv
mock
inject
variou
singledos
vaccin
present
found
time
requir
administ
lyophil
vaccin
liquid
vaccin
differ
greatest
singledos
lyophil
present
sinc
reconstitut
done
vial
novel
reconstitut
technolog
might
use
current
futur
lyophil
vaccin
varieti
reconstitut
technolog
develop
reduc
chanc
user
error
simplifi
deliveri
technolog
group
sever
categori
fulli
integr
reconstitut
technolog
includ
primari
packag
diluent
transfer
reconstitut
deliveri
featur
partial
integr
reconstitut
technolog
includ
everyth
deliveri
devic
diluent
transfer
devic
facilit
reconstitut
exist
lyophil
vaccin
vial
hybrid
reconstitut
technolog
incorpor
one
featur
technolog
current
use
highcost
pharmaceut
particularli
intend
selfadministr
patient
home
vaccin
except
diluent
transfer
devic
vial
adapt
reconstitut
technolog
vari
stage
develop
vaccin
avail
current
format
type
technolog
incorpor
packag
reconstitut
deliveri
repres
complex
reconstitut
technolog
technolog
incorpor
valv
stopper
actuat
plunger
glass
syring
cartridg
other
use
polym
tube
pouch
blister
pack
frangibl
seal
ruptur
pressur
appli
syringeor
cartridgebas
technolog
reconstitut
technolog
prefil
syring
cartridg
contain
dri
liquid
compon
separ
elastomer
intern
stopper
reconstitut
occur
mechan
pressur
appli
either
overcom
valv
plunger
push
diluent
bypass
channel
syring
parenter
deliveri
possibl
technolog
technolog
may
suitabl
vaccinedri
method
lyophil
may
repres
barrier
consider
altern
dri
method
current
use
vaccin
exampl
syring
includ
vetter
lyoject
syring
see
fig
lyogo
dual
chamber
prefil
syring
technolog
commerci
avail
vetter
lyoject
syring
incorpor
standard
stopper
bypass
channel
access
upon
advanc
plunger
allow
diluent
flow
channel
dri
powder
chamber
vetter
also
develop
market
vetter
vlk
reconstitut
cartridg
similar
mechan
action
lyogo
dual
chamber
prefil
syring
current
develop
chambersepar
stopper
novel
valv
advanc
plunger
creat
pressur
differenti
open
valv
allow
diluent
enter
duoject
design
sever
reconstitut
format
one
exampl
penprep
evo
devic
use
transfer
reconstitut
pharmaceut
vial
multidos
cartridg
use
tradit
pen
injector
integr
vial
adapt
incorpor
protect
disk
shield
user
sharp
injuri
prevent
contamin
prior
use
duoject
intervi
duoject
smartrod
xr
combin
prefil
diluent
syring
vial
adapt
vial
adapt
intervi
detach
devic
drug
reconstitut
drawn
back
syring
detach
vial
adapt
expos
standard
luer
lock
needl
attach
vial
adapt
smartrod
locat
plunger
remov
reus
duoject
intervi
plu
duoject
smartrod
plu
nearli
ident
intervi
smartrod
xr
except
locat
diluent
lyophil
content
syring
compon
prefil
lyophil
drug
attach
diluentfil
vial
bundl
copackag
lyophil
vaccin
diluent
secondari
packag
common
mani
pharmaceut
applic
well
select
vaccin
applic
rabi
vaccin
rabipur
rabi
vaccin
produc
csl
formerli
chiron
secondari
packag
contain
vaccin
vial
diluent
ampoul
syring
vaccin
diluent
suppli
vial
ampoul
primari
contain
present
diluent
provid
prefil
syring
contain
bf
ampoul
glaxosmithklin
tritanrix
hbhib
vaccin
present
includ
onedos
vial
contain
diphtheria
tetanu
pertussi
dtp
hepat
b
hepb
liquid
onedos
vial
lyophil
hib
plastic
clip
bound
vial
togeth
aid
easier
reconstitut
diluent
vial
dtphepb
vial
immedi
adjac
lyophil
vaccin
vial
plastic
clip
bind
either
vialvial
vialampoul
combin
could
reduc
advers
event
associ
incorrect
diluent
use
tradit
glass
vial
needl
syring
continu
use
standard
vaccin
formul
pharmaceut
fill
techniqu
howev
new
technolog
avail
repres
paradigm
shift
manufactur
healthcar
worker
use
use
polym
materi
enabl
design
develop
new
primari
packag
technolog
altern
materi
inform
new
research
secondari
tertiari
contain
given
challeng
vaccin
shipment
storag
cold
chain
new
technolog
reduc
volum
need
cold
chain
would
great
benefit
highincom
countri
well
lmic
new
vaccin
administr
technolog
classifi
three
major
categori
sc
im
inject
cutan
vaccin
deliveri
mucos
vaccin
deliveri
vaccin
deliv
via
sc
im
inject
needl
syring
describ
previous
highincomecountri
deliveri
eulysi
singl
vial
system
sv
compos
two
compart
lyophil
dri
powder
pharmaceut
thin
plastic
cup
rest
glass
vial
contain
diluent
see
fig
actuat
pistonlik
cap
punctur
base
plastic
cup
caus
content
fall
diluent
permit
reconstitut
needl
syring
must
use
withdraw
dose
vial
tamperevid
cap
protect
piston
cap
activ
shipment
technolog
earlystag
develop
may
potenti
widerang
applic
freezedri
inject
product
pfizer
inject
actovi
system
demonstr
similar
concept
rubber
septum
separ
diluent
dri
compart
nonstandard
glass
vial
push
plastic
cap
dislodg
septum
forc
lower
dri
compart
reconstitut
occur
actovi
use
pfizer
glucocorticoid
solucortef
solumedrol
diluent
transfer
technolog
diluent
transfer
technolog
facilit
mix
dri
liquid
compon
pharmaceut
two
separ
primari
contain
technolog
elimin
reconstitut
needl
improv
safeti
reduc
user
error
exampl
duoject
ezlink
incorpor
luer
lock
fit
socketstyl
plastic
spike
vial
adapt
socket
size
mm
mm
use
prefil
diluent
syring
use
dispens
standards
vial
lyophil
dri
powder
pharmaceut
draw
content
reconstitut
ezlink
contain
protect
disk
prevent
contamin
shield
plastic
spike
west
pharmaceut
servic
inc
allow
connect
two
vial
diluent
lyophil
pharmaceut
via
two
vialadapt
socket
plastic
spike
requir
dri
powder
vial
manufactur
vacuum
facilit
transfer
diluent
vial
reconstitut
needl
syring
use
dose
deliveri
west
needlefre
transfer
devic
luer
fit
allow
attach
luer
lock
syring
use
transfer
diluent
vial
lyophil
pharmaceut
vial
back
syring
syring
detach
needl
attach
parenter
deliveri
west
mixject
consist
cap
needl
vial
adapt
luer
lock
fit
prefil
syring
attach
diluent
syring
transfer
vial
lyophil
pharmaceut
vial
adapt
reconstitut
drawn
back
syring
vial
detach
devic
readi
drug
administr
technolog
present
fulli
partial
integr
hybrid
approach
primari
packag
diluent
transfer
reconstitut
deliveri
integr
bio
lyotip
distal
hub
incorpor
spiralshap
channel
facilit
mix
diluent
lyophil
pharmaceut
hub
requir
luer
lock
needl
syring
deliveri
nova
laboratori
hydrat
rehydr
inject
system
hydri
similar
lyotip
attach
fill
lyophil
pharmaceut
prefil
diluent
syring
see
fig
uniqu
featur
hydri
use
stabil
technolog
base
sugar
glass
amorph
solid
clear
crystal
form
sugar
pharmaceut
dri
onto
membran
integr
distal
hub
sugarbas
membran
dissolv
contact
diluent
allow
instantan
mix
diluent
lyophil
pharmaceut
past
halfcenturi
jet
injector
use
administ
hundr
million
billion
vaccin
dose
mass
campaign
human
smallpox
measl
polio
mening
influenza
yellow
fever
cholera
diseas
swine
influenza
mass
campaign
unit
state
substanti
proport
approxim
million
dose
administ
jet
inject
center
diseas
control
prevent
cdc
unpublish
data
jet
injector
also
use
wide
varieti
therapeut
drug
recent
year
devic
use
administ
antigen
human
anim
model
varieti
investig
vaccin
includ
dengu
herp
simplex
type
hivaid
japanes
enceph
malaria
melanoma
wide
varieti
investig
recombin
nucleic
acid
vaccin
deliv
preclin
clinic
trial
use
variou
jet
injector
safeti
issu
earlier
gener
munji
new
gener
dsji
develop
mani
featur
design
suitabl
global
immun
program
multius
nozzl
jet
injector
jet
injector
technolog
invent
franc
reintroduc
hypospray
patient
selfinject
insulin
us
militari
develop
highspe
system
call
pedojet
fig
unit
refer
jet
gun
wide
use
massvaccin
program
larg
bodi
clinic
literatur
show
immunogen
vaccin
deliv
jet
injector
usual
equal
sometim
better
induc
convent
needl
syring
wide
varieti
vaccin
pain
associ
jet
inject
depend
medic
vaccin
involv
insulin
nonirrit
drug
vaccin
without
adjuv
usual
report
result
reduc
equival
pain
compar
needl
alway
vaccin
aluminum
adjuv
irrit
compon
tend
result
higher
frequenc
mild
transient
local
reaction
eg
sore
edema
erythema
jet
inject
probabl
small
amount
remain
track
left
skin
bleed
less
often
ecchymosi
report
occur
jet
inject
site
frequent
needl
inject
rare
jet
stream
caus
lacer
injector
move
inject
safeti
featur
modern
dsji
reduc
risk
begin
concern
aros
potenti
iatrogen
transmiss
bloodborn
pathogen
munji
use
nozzl
inject
consecut
patient
without
interven
steril
bench
anim
studi
indic
crosscontamin
could
occur
blood
viru
remain
nozzl
orific
despit
recommend
alcohol
swab
inject
fact
supersed
theori
medejet
caus
outbreak
sever
dozen
case
hepat
b
among
patient
california
clinic
subsequ
clinic
field
bench
anim
epidemiolog
studi
ad
evid
munji
could
transmit
pathogen
patient
led
warn
discontinu
use
public
health
author
market
withdraw
pedojet
discontinu
us
militari
use
market
immun
increasingli
provid
prefil
syring
singledos
present
lowerincom
countri
servic
unicef
vaccin
commonli
deliv
multidos
vial
use
autodis
needl
syring
although
use
singledos
vial
prefil
devic
increas
altern
needl
syring
administr
sc
im
deliveri
jet
injector
deliv
vaccin
current
formul
anoth
method
earli
stage
develop
solid
dissolv
needl
vaccin
reformul
biodegrad
implant
sc
tissu
also
known
hypodermi
lie
dermi
skin
consist
mainli
lobul
adipocyt
well
connect
tissu
see
fig
blood
lymphat
vessel
transit
layer
serv
dermal
layer
skin
thick
sc
tissu
layer
vari
wide
individu
differ
age
bodi
mass
differ
bodi
site
sc
inject
vaccin
inch
needl
gaug
recommend
skin
pinch
avoid
inject
intramuscularli
needl
insert
angl
infant
younger
month
age
sc
inject
typic
given
thigh
adult
children
older
month
sc
inject
given
back
upper
arm
tricep
beneath
sc
layer
skelet
muscl
individu
muscl
cell
arrang
bundl
call
fascicl
fascicl
turn
group
bundl
within
layer
connect
tissu
form
muscl
infant
toddler
year
age
vastu
laterali
muscl
anterolater
thigh
prefer
im
inject
site
deltoid
muscl
upper
arm
use
older
children
adult
recommend
needl
length
vari
age
inject
site
bodi
mass
variat
thick
sc
layer
sc
im
rout
administr
typic
use
vaccin
rel
conveni
access
use
needl
syring
enabl
consist
deliveri
provid
adequ
reproduc
immunogen
among
individu
howev
compar
intern
extern
bodi
surfac
frequent
contact
environ
sc
im
tissu
rel
fewer
immun
cell
follow
inject
vaccin
antigen
adjuv
gener
local
innat
immun
respons
attract
apc
ingest
vaccin
packag
infiltr
dendrit
cell
see
fig
monocyt
migrat
local
drain
lymph
node
induc
band
tcell
immun
respons
gener
sc
im
inject
vaccin
tend
less
effect
produc
mucos
immun
mucos
vaccin
jet
injector
forc
liquid
high
pressur
tini
orific
produc
focus
stream
penetr
skin
deliv
medic
target
tissu
without
needl
modern
jet
injector
power
releas
energi
store
compress
metal
spring
use
compress
ga
co
n
veloc
jet
stream
exce
meter
per
second
depth
achiev
depend
primarili
power
impart
liquid
variabl
orific
diamet
distanc
nozzl
skin
angl
inject
section
focus
jet
injector
sc
im
deliveri
vaccin
devic
capabl
id
deliveri
discuss
cutan
vaccin
later
skin
vial
three
pharmajet
injector
loss
measl
mump
vaccin
viru
infect
loss
rubella
infect
two
devic
exampl
dsji
develop
vaccin
deliveri
includ
bioject
zetajet
see
fig
dci
lectrajet
see
fig
mit
medjet
see
fig
dart
use
dsji
unit
state
curtail
fda
commun
advis
vaccin
deliv
needl
syring
unless
specif
label
jet
injector
deliveri
follow
consult
fda
pharmajet
biocsl
conduct
clinic
trial
demonstr
noninferior
deliv
biocsl
afluria
influenza
vaccin
dsji
compar
needl
syring
base
data
afluria
licens
fda
deliveri
pharmajet
strati
devic
vaccin
relabel
enabl
dsji
reenter
us
market
howev
fdaapprov
languag
limit
deliveri
specif
manufactur
dsji
devic
advantag
dsji
elimin
needlestick
injuri
associ
possibl
transmiss
bloodborn
pathogen
health
worker
well
reduct
volum
sharp
wast
dispos
requir
use
dsji
syring
also
potenti
increas
accept
immun
coverag
rate
reduc
cri
observ
vaccin
deliv
infant
jet
inject
compar
needl
syring
inject
howev
like
syring
needl
dsji
syring
requir
onsit
fill
follow
vaccin
reconstitut
requir
prefil
dsji
syring
develop
pharmajet
manufactur
may
enabl
greater
effici
speed
administr
similar
old
gener
munji
use
dsji
like
entail
higher
cost
higher
cost
manufactur
dsji
syring
cost
durabl
injector
model
indic
potenti
overal
cost
save
compar
needl
syring
indirect
cost
iatrogen
diseas
result
latter
includ
vaccin
system
requir
durabl
administr
devic
distribut
vaccin
restrict
need
devic
avail
everi
poc
vaccin
deliv
cost
jet
injector
neglig
amort
mani
dose
highvaccinationvolum
set
howev
poc
lowvaccin
volum
cost
devic
may
prohibit
dissolv
needl
novel
biodegrad
implant
technolog
consist
solid
dose
vaccin
administ
subcutan
dispos
cartridg
contain
implant
load
reusabl
handheld
applic
use
ga
spring
pressur
insert
implant
skin
implant
tissu
begin
dissolv
vaccin
releas
bioneedl
technolog
group
netherland
develop
bioneedl
small
implant
biodegrad
polym
extrud
starch
fill
concentr
liquid
vaccin
freezedri
insert
sc
tissu
implant
shown
break
within
hour
dissip
deliveri
site
within
day
administr
placebo
bioneedl
implant
clinic
trial
found
adequ
safeti
accept
technolog
histolog
find
implant
site
administr
tetanu
toxoid
hepat
b
influenza
ipv
via
bioneedl
studi
anim
model
wistar
rat
dose
ipv
given
sc
im
liquid
inject
bioneedl
implant
found
produc
similar
antibodi
titer
two
immun
munji
reengin
dispos
cap
tri
prevent
contamin
blood
tissu
fluid
splash
back
onto
reusabl
nozzl
howev
inject
salin
volunt
carri
hepat
b
viru
subsequ
inject
vialsrepres
next
vaccine
clinic
mass
campaignwer
found
contain
hepat
b
antigen
highspe
microcinematographi
also
reveal
extens
splash
back
skin
inject
munji
bodi
evid
support
conclus
design
munji
inher
unsaf
use
immun
set
reus
fluid
pathway
unsteril
compon
direct
indirect
contact
consecut
patient
abandon
even
contamin
could
shown
extrem
rare
unlik
polici
maker
could
convinc
set
level
accept
risk
although
public
health
author
recommend
munji
use
vaccin
munji
continu
use
unit
state
countri
clinic
specialti
dentistri
urolog
podiatri
clean
steril
autoclav
entir
devic
fluid
path
patient
possibl
also
medjet
line
munji
receiv
licensur
multipl
countri
includ
canada
china
russia
human
applic
includ
physiatr
dermatolog
mesotherapi
indic
munji
allow
singl
health
worker
vaccin
patient
per
hour
withdraw
devic
pose
challeng
conduct
massimmun
campaign
diseas
control
program
respons
pandem
bioterror
threat
overcom
concern
munji
withdraw
new
gener
safer
dsji
develop
sinc
earli
steril
syring
cartridg
orific
nozzl
discard
patient
although
use
selfadministr
insulin
hormon
drug
sumatriptan
migrain
other
target
vaccin
administr
one
earli
system
develop
predecessor
compani
sanofi
pasteur
manufacturerprefil
imul
syring
use
miniimojet
dsji
although
demonstr
clinic
field
immunogen
safe
sever
vaccin
system
eventu
abandon
upon
corpor
merger
pioneer
dsji
vaccin
market
biojector
see
fig
introduc
unit
state
first
decad
deliv
approxim
million
im
sc
vaccin
dose
per
year
privat
public
us
navi
coast
guard
immun
clinic
unit
state
use
mani
vaccin
studi
includ
number
investig
recombin
nucleic
acid
vaccin
meet
developingworld
need
sever
dsji
develop
econom
autodis
prevent
reus
suitabl
mass
campaign
routin
immun
pharmajet
enter
market
licensur
eponym
devic
im
sc
inject
recent
studi
nowdiscontinu
dsji
found
deliveri
mmr
vaccin
meet
noninferior
criteria
comparison
needl
syring
deliveri
pharmajet
subsequ
receiv
market
clearanc
strati
devic
see
fig
first
dsji
receiv
prequalif
variou
pharmajet
model
studi
veterinari
human
applic
bench
studi
test
inject
mmr
vaccin
pig
refer
deeper
dermi
cell
grow
flatten
matur
senesc
increasingli
superfici
strata
reach
surfac
slough
main
product
cell
keratohyalin
dens
lipid
help
form
waterproof
barrier
later
edg
adjac
keratinocyt
tightli
link
desmosom
maintain
strength
epidermi
also
contribut
resist
passag
foreign
matter
molecul
topmost
horni
layer
epidermi
stratum
corneum
compos
stagger
cours
dead
keratinocytesalso
known
corneocytesin
lipid
bilay
matrix
stack
cell
thick
princip
obstacl
introduct
vaccin
antigen
cutan
vaccin
epidermi
basement
membran
lie
dermi
approxim
mm
thick
fibroblast
fine
collagen
elast
fiber
skin
organellesinclud
small
blood
vessel
lymphat
vessel
nerv
hair
follicl
sweat
sebac
glandsar
found
skin
thick
map
children
identifi
histolog
suitabl
site
cutan
vaccin
equal
import
select
skin
site
easili
access
minim
disrob
loss
privaci
smallpox
erad
volar
surfac
forearm
commonli
use
quickli
access
specif
mechan
produc
immun
respons
vaccin
antigen
introduc
skin
entir
clear
stimul
keratinocyt
produc
proinflammatori
cytokin
eg
function
apc
display
major
histocompat
complex
class
ii
antigen
human
leukocyt
antigendr
well
intercellular
adhes
epiderm
langerhan
cellsa
type
apcar
believ
play
key
role
cutan
immun
see
fig
although
dermal
dendrit
cell
wellknown
immun
system
compon
lymphocyt
mast
cell
macrophag
also
circul
resid
epidermi
dermi
immatur
langerhan
cell
resid
like
sentinel
among
keratinocyt
epidermi
compos
quarter
skin
surfac
area
effici
captur
foreign
antigen
phagocytosi
endocytosi
like
dendrit
cell
tissu
see
chapter
activ
see
fig
profession
apc
process
antigen
migrat
drain
lymph
node
matur
express
high
level
class
ii
major
histocompat
complex
molecul
present
antigen
brought
skin
thelper
lymphocyt
critic
step
subsequ
immun
respons
orchestr
latter
cell
macrodeliveri
vaccin
precis
extrem
thin
epiderm
tissu
dermi
layer
creat
technolog
challeng
result
wide
array
cutan
deliveri
method
devic
research
investig
cutan
deliveri
exist
vaccin
develop
use
mantoux
method
inject
needl
syring
see
mantoux
method
later
well
varieti
novel
devic
id
jet
injector
minineedl
microneedl
electropor
devic
microarray
patch
year
cutan
vaccin
smallpox
see
chapter
varieti
sharp
glide
pharma
unit
kingdom
also
develop
soliddos
injector
use
springload
devic
quickli
push
sc
tissu
sharp
biodegrad
implant
size
grain
rice
see
fig
soliddos
injector
test
influenza
diphtheria
h
influenza
vaccin
develop
anthrax
vaccin
potenti
benefit
technolog
class
includ
dryformat
unitdos
administr
increas
thermost
solid
vaccin
formul
comparison
liquid
formul
reduc
cold
chain
footprint
small
dose
packag
size
avoid
needl
syring
reduc
risk
needlestick
injuri
reus
potenti
reduc
number
booster
dose
slow
releas
success
demonstr
provid
improv
immunogen
challeng
develop
includ
demonstr
feasibl
formul
manufactur
solid
vaccin
implant
accept
complex
costli
administr
devic
cutan
administr
vaccin
includ
deliveri
either
dermi
epiderm
layer
skin
skin
one
first
tissu
variola
smallpox
viru
later
crossprotect
cowpox
viru
introduc
prevent
smallpox
cutan
rout
variol
involv
break
skin
sharp
instrument
use
india
china
least
earli
centuri
variol
supplant
safer
cutan
applic
materi
cowpox
lesion
vaccinia
viru
method
first
given
term
vaccin
first
publish
edward
jenner
cutan
rout
remain
standard
smallpox
vaccin
see
chapter
well
administ
bcg
prevent
tuberculosi
see
chapter
vaccin
polioviru
yellow
fever
also
deliv
rout
past
cutan
rout
demonstr
hypothet
advantag
deliveri
method
includ
potenti
enabl
dosespar
cutan
deliveri
often
associ
increas
mild
local
reaction
visibl
administr
site
less
like
result
unanticip
seriou
advers
reaction
rout
mix
result
immunogen
id
rout
report
varieti
live
attenu
inactiv
subunit
vaccin
includ
dosespar
studi
current
avail
vaccin
formul
well
investig
vaccin
particularli
dna
vaccin
classic
id
inject
bolu
liquid
deposit
dermi
rais
visibl
bleb
tradit
mantoux
method
varieti
novel
deliveri
method
technolog
develop
deliv
vaccin
skin
goal
improv
eas
accept
safeti
vaccin
b
take
advantag
potenti
skin
tissu
enhanc
immunogen
enabl
dosespar
outermost
layer
skin
epidermi
see
fig
stratifi
squamou
epithelium
usual
thick
mm
palm
sole
stratum
malpighi
layer
primari
compon
epidermi
divid
grow
keratinocyt
serv
structur
functionlimit
passag
water
moleculesand
immunolog
role
keratinocyt
germin
basement
membran
demarc
boundari
epidermi
cutan
administr
id
needl
inject
use
mantoux
techniqu
bcg
also
deliv
cutan
multipl
punctur
devic
scarif
jet
injector
bifurc
needl
fig
multitin
devic
mantoux
method
remain
standard
deliveri
method
see
fig
bifurc
needl
benjamin
rubin
invent
bifurc
needl
see
fig
wyeth
waiv
royalti
could
produc
smallpox
erad
devic
hold
approxim
fluid
capillari
action
tine
appli
perpendicularli
skin
use
onefifth
typic
dose
volum
need
earlier
multiplepressur
method
instrument
use
penetr
epidermi
avoid
penetr
unnecessarili
deeper
dermi
inocul
cowpox
vaccinia
viru
includ
scarif
needl
scalpel
lancet
knife
rub
vaccin
result
lesion
twirl
rotari
lancet
drop
vaccin
skin
multiplepressur
method
press
straight
surgic
needl
sideway
skin
drop
vaccin
multitin
devic
consist
multipl
short
needl
circular
squar
array
dip
solut
press
skin
also
use
bcg
vaccin
prevent
diseas
mycobacterium
tuberculosi
origin
administ
oral
see
chapter
safeti
concern
prompt
shift
led
market
approv
europ
id
deliveri
intanza
idflu
product
contain
either
viral
hemagglutinin
per
strain
per
ml
adult
age
year
full
nondosagespar
age
year
older
sanofi
pasteur
us
brand
id
influenza
vaccin
fluzon
intraderm
similarli
contain
per
strain
found
induc
geometr
mean
titer
hemagglutinationinhibit
antibodi
noninferior
control
patient
receiv
convent
fluzon
im
rout
per
strain
fda
licens
vaccin
uniqu
prefil
deliveri
system
indic
use
patient
year
age
sever
countri
eg
canada
australia
new
zealand
also
licens
sanofi
influenza
vaccin
soluvia
minineedl
deliveri
system
fillonsit
version
soluvia
minineedl
syring
use
rabi
vaccin
clinic
trial
demonstr
protect
seroconvers
compar
full
dose
im
rout
preclin
anim
experi
deliveri
devic
produc
good
immun
respons
anthrax
recombin
protect
antigen
convent
hemagglutinin
plasmid
dna
antigen
influenza
live
recombin
yellow
fever
vector
japanes
enceph
vaccin
novosani
develop
anoth
prefil
minineedl
devic
vaxid
test
deliveri
salin
human
star
syring
develop
fillonsit
minineedl
id
syring
see
fig
star
id
devic
design
low
cost
suitabl
use
exist
vial
format
fill
integr
plastic
spike
autodis
featur
clinic
studi
assess
inject
perform
devic
plan
minineedl
devic
facilit
id
deliveri
enabl
dosespar
potenti
vaccin
retain
familiar
interfac
use
method
common
im
needl
syring
inject
id
inject
soluvia
devic
frequent
produc
characterist
wheal
skin
indic
correct
mantoux
inject
techniqu
educ
healthcar
worker
may
need
prefil
present
soluvia
vaxid
offer
addit
benefit
eas
use
dose
accuraci
expens
requir
much
cold
chain
storag
space
vial
present
recent
develop
lowcost
fillonsit
devic
star
id
syring
demonstr
perform
clinic
could
appropri
requir
lmic
immun
program
hollow
microneedl
hollow
microneedl
deliv
liquid
vaccin
intraderm
share
attribut
needlebas
technolog
id
deliveri
describ
previous
see
minineedl
intraderm
adapt
earlier
hollow
microneedl
design
inject
therapeut
liquid
tini
lumen
use
either
syring
small
wearabl
pump
flow
rate
microneedl
measur
remark
mlmin
per
cannula
common
length
short
enough
theori
painless
would
reach
nerv
end
dermi
micronjet
devic
develop
nanopass
uniqu
avail
licens
steril
dispos
microneedl
devic
consist
three
hollow
microneedl
height
bevel
pyramid
shape
mount
adapt
luer
interfac
fit
onto
convent
syring
liquid
vaccin
drug
see
fig
clear
fda
inject
drug
approv
id
deliveri
also
hold
ce
mark
market
europ
adult
volunt
vaccin
intraderm
similar
micronjet
version
four
microneedl
height
requir
higher
viru
concentr
simplic
portabl
economi
greatli
facilit
latter
half
smallpox
erad
particularli
asia
east
africa
mantoux
method
needl
techniqu
classic
id
inject
use
bcg
develop
earli
centuri
felix
mendel
separ
charl
mantoux
administr
tuberculin
replac
purifi
protein
deriv
use
diagnosi
tuberculosi
infect
refer
mantoux
method
see
fig
procedur
becom
common
rout
id
inject
bcg
rabi
vaccin
although
latter
typic
deliv
intramuscularli
research
found
reduc
dose
rabi
vaccin
deliv
via
id
similarli
effect
postexposur
preexposur
prophylaxi
regimen
high
cost
cellcultur
rabi
vaccin
recommend
id
deliveri
resourceconstrain
set
sinc
rout
wide
use
develop
world
particularli
asia
mantoux
techniqu
shortbevel
finegaug
needl
usual
gaug
insert
bevel
angl
slightli
stretch
skin
often
volar
surfac
forearm
tip
advanc
approxim
mm
entir
bevel
cover
upon
inject
fluid
proper
locat
bevel
dermi
creat
bleb
wheal
basement
membran
epidermi
stretch
fluid
see
fig
leakag
onto
skin
indic
insuffici
penetr
cover
bevel
failur
produc
bleb
indic
improperli
deep
locat
fluid
sc
tissu
drawback
mantoux
method
train
skill
extra
time
need
accomplish
correctli
intraderm
adapt
novel
id
adapt
see
fig
design
improv
eas
consist
tradit
mantoux
techniqu
see
fig
fit
convent
syring
fix
needl
guid
needl
appropri
posit
skin
produc
desir
bleb
devic
market
west
pharmaceut
servic
fda
clearanc
clinic
studi
id
adapt
found
reliabl
produc
bleb
regardless
orient
needl
bevel
inject
similar
fillonsit
minineedl
devic
id
adapt
potenti
rel
lowcost
option
increas
eas
reliabl
id
inject
angl
inject
mimic
mantoux
techniqu
may
also
serv
train
tool
user
inexperienc
mantoux
one
challeng
devic
design
syring
specif
must
pair
particular
brand
syring
minineedl
cutan
vaccin
gener
divers
terminolog
appli
microscop
project
perfor
superfici
skin
deliv
drug
vaccin
chapter
use
term
minineedl
hollow
project
mm
longer
liquid
deliveri
term
microneedl
refer
hollow
project
shorter
microarray
patch
array
solid
project
without
lumen
shorter
patch
deliv
vaccin
dri
format
classifi
needl
circumv
amount
skill
time
need
success
mantoux
inject
bd
develop
prefil
glass
syring
stake
minineedl
project
mm
beyond
depthlimit
hub
intuit
perpendicular
insert
skin
see
fig
term
soluvia
microdeliveri
system
licens
exclus
sanofi
pasteur
certain
vaccin
applic
sanofi
pasteur
undertook
seri
clinic
trial
trival
inactiv
coat
minineedl
mm
long
follow
electropor
smallpox
antigen
plasmid
dna
dri
onto
tip
array
insert
skin
mice
follow
six
electr
puls
induc
protect
smallpox
challeng
prostat
cancer
dna
vaccin
similarli
administ
electropor
promis
enabl
technolog
dna
vaccin
lower
efficaci
tradit
deliveri
method
accept
challeng
particularli
im
electropor
devic
although
id
devic
found
toler
cost
complex
devic
could
preclud
use
lowresourc
set
jet
inject
sinc
multius
nozzl
jet
injector
see
subcutan
intramuscular
inject
jet
inject
earlier
allow
id
deliveri
smallpox
bcg
vaccin
via
special
nozzl
standoff
achiev
shallow
penetr
requir
compar
im
sc
inject
discontinu
use
munji
dsji
use
id
inject
devic
biojector
bioject
zetajet
spacer
ad
nozzl
intend
sc
deliveri
creat
gap
orific
skin
weaken
jet
provid
space
bleb
leav
dose
skin
design
mit
medjet
line
gaspow
jet
injector
mit
dart
springpow
dsji
achiev
id
deliveri
variabl
pressur
set
allow
user
reduc
forc
inject
stream
pharmajet
tropi
fig
bioject
id
pen
see
fig
two
new
springpow
dsji
design
sole
id
deliveri
volum
pedojet
much
lesser
extent
munji
administ
ten
million
smallpox
vaccin
dose
first
half
smallpox
erad
program
south
america
west
africa
late
earli
invent
simpler
swifter
bifurc
needl
munji
also
deliv
yellow
fever
bcg
vaccin
id
rout
well
variou
tuberculosi
skin
test
antigen
howev
variat
subsequ
tuberculosi
skin
test
reaction
size
deliv
munji
led
discourag
jet
injector
use
bcg
tuberculosi
skin
test
achiev
polio
erad
goal
inject
ipv
introduc
worldwid
supplement
use
oral
polioviru
vaccin
opv
howev
ipv
expens
produc
difficult
deliv
campaign
set
opv
promot
search
costsav
strategi
also
avoid
introduct
needl
polio
erad
program
recent
clinic
research
compar
full
dose
ipv
given
intramuscularli
ml
id
deliveri
ml
either
needlefre
jet
injector
mantoux
techniqu
studi
evalu
primari
seri
immun
infant
found
equival
seroconvers
rate
other
shown
reduc
respons
id
jet
inject
trial
conduct
infant
id
deliveri
reduc
dose
ipv
result
lower
titer
neutral
antibodi
whether
report
geometr
mean
titer
median
titer
whether
studi
perform
infant
infant
receiv
supplement
dose
ipv
suggest
howev
detect
neutral
antibodi
titer
suffici
prevent
paralyt
diseas
clinic
trial
use
singl
dose
ipv
boost
immun
previous
immun
children
adult
gener
found
id
deliveri
ml
receiv
reduc
singl
dose
per
strain
full
dose
im
rout
licens
alpharix
fluarix
glaxosmithklin
season
influenza
vaccin
day
three
studi
arm
develop
compar
increas
antibodi
titer
local
reaction
frequent
micronjet
im
rout
mild
transient
similar
dosagespar
trial
monoval
influenza
vaccin
trival
vaccin
confirm
compar
superior
immun
respons
id
rout
versu
im
micronjet
also
studi
reduceddos
deliveri
ipv
varicellazost
vaccin
anoth
hollow
microneedl
system
hollow
microstructur
transderm
system
hmt
patientcontact
surfac
contain
microneedl
height
whose
lumina
diamet
deliv
liquid
volum
rang
ml
springpow
devic
contain
liquid
drug
prefil
glass
dose
chamber
upon
trigger
spike
pierc
stopper
chamber
dose
pass
forc
slowli
period
minut
microneedl
skin
upper
arm
thigh
adhes
keep
system
place
deliveri
complet
deliveri
equin
tetanu
antitoxin
swine
model
deliveri
monoclon
antibodi
result
pharmacokinet
profil
tetanu
antitoxin
similar
dosag
via
sc
inject
industri
academ
group
pursu
develop
hollow
microneedl
includ
debiotech
georgia
institut
technolog
hollow
microneedl
advantag
similar
needlebas
id
devic
deliveri
liquid
vaccin
increas
reliabl
eas
id
inject
potenti
enabl
vaccin
dosespar
clinic
studi
found
deliveri
influenza
vaccin
nanopass
micronjet
hollow
microneedl
devic
enhanc
immunogen
compar
dose
vaccin
deliv
id
mantoux
method
suggest
reliabl
shallow
depth
deliveri
hollow
microneedl
devic
may
enabl
superior
immun
respons
howev
separ
needl
vial
adapt
requir
fill
syring
hollow
microneedl
devic
convent
vial
ad
step
requir
inject
prefil
hollow
microneedl
technolog
develop
would
simplifi
usag
like
increas
cost
cold
chain
requir
electropor
electropor
use
short
electr
puls
produc
temporari
pore
nanometerrang
diamet
intercellular
lipid
matrix
stratum
corneum
remain
open
permeabl
hour
vitro
vivo
preclin
studi
techniqu
demonstr
skin
entri
larger
molecul
heparin
kda
peptid
protein
lutein
hormonereleas
hormon
nucleic
acid
potenti
extens
use
investig
dna
vaccin
anim
human
inovio
cellectra
seri
electropor
devic
ichor
trigrid
deliveri
system
capabl
id
im
deliveri
hollow
needl
inject
drug
convent
parallel
solid
needl
surround
inject
dose
creat
current
gener
pore
target
muscl
tissu
devic
test
preclin
clinic
deliveri
sever
dna
vaccin
includ
hpv
hiv
malaria
tuberculosi
result
demonstr
improv
immunogen
dna
antigen
electropor
appli
noninvas
surfac
electropor
devic
also
develop
inovio
may
better
accept
easi
vax
relat
derma
vax
epiderm
electropor
system
combin
applic
antigenor
drugdeliveri
offer
advantag
speed
simplic
patient
accept
well
abil
use
offtheshelf
vaccin
without
reformul
challeng
includ
develop
devic
reliabl
deliv
small
id
dose
correct
depth
obtain
clinic
data
licens
vaccin
id
deliveri
dsji
higher
cost
dsji
devic
compar
id
needl
syring
dose
immunogen
often
meet
noninferior
criteria
compar
fulldos
im
deliveri
recent
clinic
trial
bcg
vaccin
given
via
id
found
dsji
deliveri
mantoux
method
deliveri
similar
safeti
immunogen
vaccin
studi
id
deliveri
dsji
includ
hiv
influenza
dengu
hpv
jet
injector
id
induc
robust
immun
responsesoften
better
equival
dosag
control
inject
sc
routea
well
protect
lethal
viral
challeng
coat
bcg
microarray
platform
highli
immunogen
guinea
pig
robust
cellmedi
respons
lung
spleen
compar
mantoux
inject
similarli
plasmid
dna
antigen
hepat
c
coat
needl
length
prime
specif
cytotox
lymphocyt
vaccin
mice
readili
convent
needl
inactiv
rotaviru
vaccinedevelop
avoid
inhibitori
effect
matern
antibodi
live
oral
vaccin
coat
onto
microarray
platform
found
immunogen
anim
model
anoth
center
microarray
research
univers
queensland
nearbi
compani
vaxxa
australia
develop
novel
nitrogen
ga
jetdri
method
coat
antigen
onto
silicon
overcom
challeng
dipcoat
close
space
project
still
allow
antigen
elut
within
minut
upon
skin
entri
nanopatch
technolog
among
smallest
project
less
length
project
per
squar
centimet
silicon
chip
see
fig
achiev
dosagespar
compar
im
rout
mous
model
influenza
antigen
studi
good
result
murin
model
platform
includ
hpv
chikungunya
dna
plasmid
vaccin
herp
simplex
viru
west
nile
viru
viral
vector
dna
vaccin
malaria
research
develop
coat
microarray
patch
vaccin
also
underway
mani
group
experiment
placement
solid
microstructur
transderm
system
microarray
patch
devic
human
volunt
found
well
toler
nonintimid
pain
georgia
institut
technolog
microarray
patch
without
coat
use
clinic
studi
assess
usabl
complet
skin
penetr
appli
selfadministr
studi
particip
indic
would
will
vaccin
influenza
vaccin
microarray
patch
avail
focu
group
discuss
public
privat
healthcar
provid
also
posit
toward
microarray
patch
chang
convent
needl
syring
deliveri
microarray
patch
also
allow
use
dri
formul
improv
vaccin
thermost
reduc
need
cold
chain
storag
exampl
formul
prepar
georgia
institut
technolog
key
ingredi
carboxycellulos
matrix
dri
coat
trehalos
one
sever
sugar
includ
sucros
found
use
protect
protein
antigen
damag
dri
freez
therebi
improv
vaccin
thermost
microarray
patch
potenti
enabl
dose
spare
vaccin
patch
may
also
provid
adjuvantlik
effect
increas
local
cell
death
although
potenti
transform
technolog
vaccin
deliveri
microarray
patch
earli
stage
develop
use
vaccin
challeng
includ
gener
clinic
evid
scale
manufactur
process
requir
wear
time
microarray
patch
yet
fix
differ
among
design
preclin
studi
wear
time
microarray
patch
vaccin
greater
minut
also
around
minut
ideal
deliveri
time
would
suffici
rapid
allow
quick
applic
remov
proper
dispos
healthcar
worker
longer
wear
time
requir
success
deliveri
earli
remov
risk
lead
possibl
insuffici
antigen
deliveri
well
dispos
vaccin
antigen
outsid
locat
supervis
immun
session
vaccin
recipi
remain
clinic
microarray
patch
microarray
patch
also
refer
microneedl
patch
deliv
solid
formul
vaccin
skin
differ
set
potenti
benefit
develop
challeng
liquiddeliveri
technolog
cutan
vaccin
describ
microarray
patch
meet
mani
criteria
practic
ideal
vaccin
deliveri
system
needl
free
prefil
unitdos
dri
format
potenti
increas
thermost
also
ship
common
ship
method
mail
potenti
selfadminist
administ
minim
train
personnel
microarray
patch
subdivid
solidco
dissolv
type
solidco
microarray
patch
common
strategi
pursu
number
commerci
academ
team
carri
antigen
across
stratum
corneum
coat
vaccin
onto
solid
microscop
project
held
variabl
period
time
dermi
epiderm
layer
depend
height
antigen
drug
elut
diffus
microarray
patch
technolog
design
applic
finger
pressur
develop
found
mechan
applic
need
consist
skin
penetr
date
therapeut
drug
applic
reach
advanc
stage
develop
vaccin
nevertheless
substanti
amount
preclin
research
conduct
vaccin
sever
earlystag
vaccin
clinic
trial
progress
one
exampl
drugcoat
microarray
patch
investig
zosano
pharma
zp
patch
platform
formerli
known
macroflux
titanium
project
vari
height
pack
area
cm
densiti
tinescm
insert
springmount
applic
held
place
adhes
patch
advanc
applic
microarray
patch
deliveri
parathyroid
hormon
treat
osteoporosi
alreadi
studi
clinic
erythropoietin
treat
anemia
regard
vaccin
applic
zosano
pharma
zpflu
influenza
vaccin
patch
appli
minut
onto
skin
trend
toward
increas
titer
seroprotect
compar
im
control
inject
preclin
studi
system
demonstr
deliveri
ovalbumin
oligonucleotid
peptid
hormon
desmopressin
compani
report
anim
work
tetanu
diphtheria
lyme
diseas
hepat
b
dna
vaccin
antigen
anoth
coat
microarray
patch
platform
solid
microstructur
transderm
system
drugcoat
pyramid
project
vari
height
array
microarray
patch
mount
adhes
patch
densiti
per
squar
centimet
applic
skin
manual
fingerthumb
press
patch
devic
springpow
applic
shown
elsewher
coat
microarray
patch
said
hold
mg
activ
pharmaceut
ingredi
rabbit
model
coat
tetanu
toxoid
aluminum
adjuv
variou
ratio
induc
antibodi
use
fraction
standard
im
dosag
swine
model
viruslik
protein
hbsag
demonstr
dosag
spare
via
solid
microstructur
transderm
system
compar
antigen
deliv
im
control
rout
recent
public
registr
describ
safeti
trial
without
antigen
georgia
institut
technolog
pioneer
center
microarray
technolog
work
emori
univers
conduct
numer
studi
coat
microarray
patch
anim
model
cutan
vaccin
deliveri
seri
murin
studi
use
solid
metal
microarray
patch
coat
inactiv
influenza
virus
cutan
vaccin
superson
speed
uniqu
method
vaccin
develop
earli
oxford
bioscienc
year
renam
powderject
acquir
chiron
spun
powderm
final
acquir
pfizer
deliveri
either
reusabl
xr
seri
singleus
dispos
nd
seri
devic
see
fig
nd
seri
target
commerci
convent
protein
antigen
deliveri
epiderm
powder
immun
spraydri
powder
suitabl
densiti
size
econom
manufactur
formul
may
obstacl
dna
vaccin
deliv
pmed
plasmid
code
desir
antigen
coat
onto
gold
bead
diamet
deposit
epiderm
apc
elut
transcrib
number
preclin
studi
variou
anim
model
conduct
human
trial
dna
vaccin
contain
one
order
magnitud
less
antigen
amount
use
im
rout
induc
humor
cellular
immun
respons
hepat
b
subject
previous
vaccin
convent
vaccin
pmed
vaccin
also
studi
dna
prime
trial
malaria
vaccin
produc
seroprotect
immun
respons
dna
vaccin
season
strain
influenza
reduc
influenza
symptom
viral
shed
human
challeng
hepat
b
influenza
trial
cite
earlier
sever
local
reaction
erythema
swell
flake
crust
format
occur
nearli
subject
albeit
resolv
day
skin
discolor
howev
persist
day
subject
day
inject
site
beyond
month
patient
longterm
followup
antidoublestrand
dna
antibodi
detect
deposit
gold
particl
studi
pig
deposit
stratum
corneum
epidermi
eventu
slough
exfoli
day
day
administr
particl
remain
basal
epiderm
layer
macrophag
dermi
region
lymph
node
preclin
studi
epiderm
powder
immun
pmed
murin
porcin
primat
model
shown
immunogen
protect
either
powder
dna
plasmid
antigen
variou
pathogen
includ
eurasian
encephalit
virus
hantavirus
hiv
influenza
malaria
sever
acut
respiratori
syndrom
sar
coronaviru
smallpox
venezuelan
equin
enceph
abrasiontranscutan
deliveri
variou
commerci
patch
deliveri
system
develop
sinc
demonstr
abil
certain
therapeut
agent
eg
scopolamin
nitroglycerin
clonidin
estradiol
fentanyl
nicotin
testosteron
diffus
passiv
bare
untreat
skin
without
use
activ
technolog
enhanc
howev
passiv
diffus
usual
work
small
molecul
certain
physic
characterist
thu
anim
model
immun
onto
bare
untreat
skin
newer
method
facilit
antigen
deliveri
epidermi
involv
painlessli
strip
abrad
skin
increas
permeabl
barrier
stratum
corneum
varieti
simpl
tool
use
remov
stratum
corneum
common
cellophan
adhes
tape
may
appli
skin
pull
away
carri
away
dead
keratinocyt
repetit
tapestrip
shown
enhanc
cytotox
tcell
cytokin
immun
respons
subsequ
applic
variou
antigen
adjuv
otherwisesupervis
environ
deliveri
increas
vaccin
time
thu
reduc
throughput
might
neg
impact
overal
program
effici
coat
microarray
patch
might
consid
sharp
infecti
wast
materi
use
contact
bodili
fluid
risk
needlestick
injuri
remain
consider
need
applic
whether
separ
integr
patch
reliabl
appli
microarray
patch
anoth
key
question
cost
logist
implic
immun
program
visual
auditori
indic
may
also
import
reassur
user
recipi
vaccin
deliv
correctli
dissolv
microarray
patch
eleg
strategi
decreas
risk
intent
reus
inadvert
contact
use
microarray
patch
sharp
dissolv
skin
hydrat
thu
releas
antigen
common
matrix
dissolv
microarray
patch
hard
enough
penetr
skin
carboxymethylcellulos
gener
recogn
safe
parenter
deliveri
fda
among
compound
georgia
institut
technolog
emori
univers
encapsul
inactiv
influenza
vaccin
viru
biocompat
polym
dissolv
within
minut
applic
skin
see
fig
robust
antibodi
cellular
immun
respons
provid
complet
protect
lethal
challeng
mice
clinic
trial
progress
sever
sugar
trehalos
sucros
maltos
found
key
ingredi
stabil
maintain
potenc
antigen
process
form
dissolv
microarray
patch
studi
shown
month
stabil
measl
vaccin
microarray
patch
formal
thermost
studi
need
assess
whether
formul
would
resist
heat
degrad
allow
transport
storag
outsid
cold
chain
corium
intern
develop
microcor
dissolv
microarray
patch
integr
applic
adher
skin
see
fig
theraject
develop
drugmat
vaxmat
dissolv
microarray
patch
investig
preclin
deliveri
sever
pharmaceut
includ
influenza
vaccin
theraject
patch
design
manual
applic
without
applic
applic
also
develop
need
reliabl
deliveri
japan
cosm
market
cosmet
microhyala
microarray
patch
contain
hyaluron
dissolv
minut
phase
clinic
trial
use
technolog
deliv
influenza
vaccin
conduct
mani
other
also
pursu
dissolv
microarray
patch
advantag
challeng
dissolv
microarray
patch
similar
solidco
patch
see
solidco
microarray
patch
earlier
import
distinct
dissolv
patch
leav
sharp
wast
powder
inject
transfect
cell
kinet
method
deposit
dnacoat
gold
particl
pioneer
helio
pd
gene
accel
injector
becom
standard
bench
tool
biolist
deliveri
nucleic
acid
plasmid
wide
varieti
plant
anim
transfect
express
code
gene
deliveri
dna
skin
overcom
usual
polar
thelper
cell
type
respons
dna
deliv
muscl
devic
unavail
human
vaccin
patent
right
held
powderm
proprietari
term
epiderm
powder
immun
particlemedi
epiderm
deliveri
pmed
refer
use
helium
ga
blow
powder
protein
polysaccharid
inactiv
pathogen
epiderm
powder
immun
dnacoat
particl
pmed
epidermi
held
applic
preclin
studi
microenhanc
array
devic
conduct
use
hepat
b
anthrax
japanes
enceph
vaccin
human
trial
howev
rabi
vaccin
appli
four
rub
devic
four
separ
deltoid
skin
site
detect
immun
respons
three
dose
technolog
abrad
skin
enhanc
transderm
deliveri
potenti
low
cost
accept
user
compat
vaccin
suitabl
use
varieti
vaccin
set
although
devic
design
must
ensur
eas
correct
use
reproduc
dose
effect
vaccin
challeng
technolog
particularli
disappoint
result
intercel
etec
vaccin
result
field
cutan
vaccin
focus
mainli
technolog
inject
deliv
vaccin
skin
rather
reli
passiv
diffus
micropor
micropor
also
term
thermopor
use
heat
vapor
tini
open
stratum
corneum
passport
system
develop
altea
own
nitto
denko
heat
gener
dispos
array
metal
filament
held
momentarili
skin
devic
size
comput
mous
see
fig
activ
electr
puls
induc
heat
filament
adhes
patch
contain
vaccin
therapeut
agent
appli
micropor
creat
hairless
mous
model
techniqu
elicit
greater
cellular
humor
respons
adenoviru
vaccin
intact
skin
well
protect
surrog
tumor
challeng
intact
skin
model
adenovirusvector
melanoma
antigen
appli
micropor
roughli
doubl
averag
onset
time
tumor
challeng
protect
one
six
mice
compar
none
eight
vaccin
control
intact
skin
micropor
recombin
influenza
hemagglutinin
protect
balbc
mice
challeng
lethal
strain
skin
micropor
also
permit
passag
insulin
pharmacokinet
human
trial
histor
control
direct
allow
interstiti
fluid
extract
potenti
glucos
monitor
anoth
devic
similarli
gener
micropor
heat
induc
radiofrequ
wave
viaderm
differ
techniqu
use
short
puls
superh
steam
microlit
amount
remov
stratum
corneum
pantec
biosolut
develop
laser
micropor
platform
could
also
use
cutan
vaccin
deliveri
micropor
system
provid
reliabl
mean
form
pore
stratum
corneum
enhanc
transderm
deliveri
although
dose
reproduc
vaccin
deliv
across
skin
follow
procedur
remain
verifi
devic
design
rapid
use
accept
level
local
reactiv
micropor
system
cost
distribut
reusabl
devic
could
challeng
lowresourc
set
particularli
due
electr
power
requir
human
pathogen
initi
infect
mucos
portal
entryth
respiratori
gastrointestin
genitourinari
tract
mucos
immun
prevent
infect
contrast
system
immun
clear
infect
success
invas
limit
replic
destroy
pathogen
ideal
mucos
system
immun
rais
target
pathogen
strong
mucos
immun
may
enhanc
benefit
immun
diseas
exampl
prevent
initi
infect
mucos
immun
reduc
risk
transmiss
skin
mice
similarli
rub
gauz
emeri
paper
pumic
skin
remov
cell
abras
effect
found
enhanc
immun
respons
human
applic
cyanoacryl
glue
follow
strip
skin
appli
antigen
expos
hair
follicl
describ
practic
question
among
method
strip
skin
perhap
advanc
one
combin
step
use
remark
potent
adjuv
heatlabil
enterotoxin
lt
escherichia
coli
effort
origin
champion
gregori
glenn
first
walter
reed
armi
institut
research
iomai
corpor
later
intercel
vaccin
patient
hold
skin
devic
skin
prepar
system
see
fig
push
button
pull
tab
control
pressur
appli
sandpap
strip
gentli
abrad
remov
approxim
stratum
corneum
patch
contain
lt
antigen
alon
lt
adjuv
anoth
antigen
appli
skin
process
call
transcutan
immun
lt
alon
intend
induc
immun
enterotoxigen
e
coli
etec
caus
travel
diarrhea
vibrio
cholera
without
etec
colon
factor
initi
random
blind
field
trial
among
travel
guatemala
mexico
found
efficaci
patch
lt
alon
protect
moder
sever
diarrhea
intercel
report
mix
result
two
followup
field
studi
pivot
phase
iii
trial
travel
diarrhea
n
guatemala
mexico
trial
primari
target
end
point
greater
efficaci
moder
sever
etec
diarrhea
met
find
approxim
protect
effect
frequenc
caus
diarrhea
howev
reduct
incid
ltposit
diarrhea
degre
sever
along
signific
reduct
durat
sever
diarrhea
caus
patch
also
induc
measur
immun
respons
well
toler
smaller
phase
ii
trial
india
n
lt
patch
also
reach
target
end
point
perhap
low
attack
rate
approxim
ltposit
etec
result
two
trial
intercel
discontinu
work
lt
patch
travel
diarrhea
still
pursu
use
skin
prepar
system
devic
applic
appli
intercel
lt
patch
near
site
inject
parenter
influenza
vaccin
applic
refer
vaccin
enhanc
patch
found
improv
hemagglutin
inhibit
titer
serum
mucosa
young
age
mice
increas
hemagglutin
inhibit
titer
show
improv
trend
adult
human
volunt
older
year
age
preclin
studi
applic
use
lt
structur
similar
cholera
toxin
cutan
adjuv
result
improv
immun
respons
challeng
protect
anim
model
tetanu
anthrax
malaria
helicobact
pylori
shiga
toxinproduc
strain
enterohemorrhag
e
coli
method
take
advantag
lowcost
fabric
techniqu
adapt
microelectron
industri
convert
silicon
metal
materi
array
micrometerto
millimeters
microrasp
design
abrad
stratum
corneum
one
exampl
microenhanc
array
also
known
onvax
investig
technolog
scrape
skin
topic
applic
antigen
therapeut
agent
microenhanc
array
consist
squar
round
chip
contain
area
silicon
plastic
microproject
mount
fingerfor
deliveri
lower
respiratori
tract
small
particl
inhal
via
nose
mouth
share
common
pathway
pharynx
larynx
trachea
bifurc
trachea
right
left
bronchi
start
seri
bifurc
provid
surfac
trap
airborn
particl
small
slowmov
particl
succeed
navig
tortuou
passag
deposit
lower
airway
smallest
particl
may
reach
alveoli
rapidli
absorb
system
circul
complex
branch
lung
passag
also
result
astonish
alveolar
surfac
area
exceed
human
adult
male
lower
airway
human
typic
organ
lymphoid
tissu
abund
intraepitheli
dendrit
cell
alveolar
macrophag
process
antigen
see
fig
im
sc
id
vaccin
deliveri
induc
mucos
system
immun
administr
vaccin
mucos
tissu
tend
induc
strongest
mucos
respons
sever
cell
type
activ
mucos
antigen
surveil
system
although
epitheli
cell
may
play
role
immun
respons
critic
target
includ
profession
apc
dendrit
cell
macrophag
present
mucos
tissu
see
fig
f
case
alveolar
macrophag
mucos
surfac
see
fig
phagocytosi
foreign
microparticl
import
compon
innat
mucos
immun
mucos
antigen
surveil
mucos
surfac
expos
myriad
nonpathogen
macromolecul
mechan
downregul
immun
respons
antigen
exposur
thu
potenti
induc
immunolog
toler
must
consid
develop
mucos
immun
strategi
dendrit
cell
activ
throughout
mucos
tissu
present
high
concentr
mucosalassoci
lymphoid
tissu
includ
tonsil
adenoid
peyer
patch
see
fig
mucosalassoci
lymphoid
tissu
also
rich
microfold
cell
special
epitheli
cell
apic
surfac
take
macromolecul
virus
bacteria
endocytosi
basal
surfac
cell
invagin
pocket
commun
extracellular
space
host
collect
lymphocyt
dendrit
cell
see
fig
cell
transfer
endocytos
materi
apc
process
apc
mucosa
track
region
lymph
node
bcell
activ
occur
b
cell
preferenti
switch
iga
plasmablast
home
back
expos
mucos
tissu
provid
antigenspecif
iga
protect
cell
also
home
back
mucos
site
play
major
role
mucos
immunolog
memori
respons
lymphocyt
expos
antigen
one
mucos
site
respiratori
tract
migrat
provid
protect
remot
mucos
site
vagina
integr
network
immun
cell
tissu
known
common
mucos
immun
system
studi
vaccin
result
higher
vagin
iga
titer
vagin
vaccin
almost
everi
mucos
surfac
avail
administ
vaccin
studi
varieti
antigen
anim
model
includ
oral
respiratori
rectal
vagin
ocular
tissu
gener
respiratori
gastrointestin
tract
organ
lymphoid
tissu
site
capac
induct
immun
respons
sever
human
vaccin
licens
use
success
deliveri
enter
tract
oral
ingest
preclin
studi
investig
potenti
util
administ
oral
vaccin
target
oral
mucosa
rather
other
addit
prevent
clinic
diseas
prevent
infect
mucos
surfac
may
especi
import
diseas
effect
system
immun
difficult
achiev
tuberculosi
aid
describ
extern
surfac
human
bodi
protect
keratin
stratifi
squamou
epithelium
compos
outermost
layer
skin
contrast
intern
surfac
mucos
tract
protect
varieti
epitheli
type
commensur
differ
function
gastrointestin
respiratori
genitourinari
tract
nonkeratin
stratifi
squamou
epithelium
predomin
oral
caviti
oropharynx
vagina
anal
canal
ciliat
noncili
pseudostratifi
epithelia
line
nasal
airway
nasopharynx
bronchi
variou
special
simpl
singl
layer
epithelia
found
mucos
site
exampl
enterocyt
gastrointestin
tract
microvilli
apic
surfac
facilit
nutrient
absorpt
pulmonari
squamou
alveolar
cell
extrem
thin
permit
diffus
oxygen
gase
alveoli
vascular
system
lack
skin
protect
layer
keratin
mucos
epitheli
surfac
protect
pathogen
invas
sever
altern
mechan
first
complex
dynam
mucu
coat
restrict
access
mucos
epitheli
surfac
next
proteolyt
enzym
abund
mani
mucos
surfac
highli
acid
gastric
environ
degrad
pathogen
entri
small
intestin
mucos
system
also
dynam
move
potenti
threat
limit
durat
exposur
exampl
ciliat
epithelia
upper
lower
respiratori
tract
continu
drive
mucu
layer
content
oropharynx
swallow
degrad
gastric
acid
peristalsi
gastrointestin
mechan
result
eventu
expuls
gastrointestin
content
final
import
mucos
microbiota
prevent
infect
promot
healthi
immun
respons
becom
increasingli
realiz
addit
physic
defens
describ
mucos
immun
provid
addit
defens
layer
prevent
infect
innat
mucos
immun
factor
includ
endogen
antimicrobi
peptid
defensin
cathelicidin
protein
lysozym
lactoferrin
also
resid
mani
mucos
surfac
inhibit
pathogen
incurs
pathogen
invas
defens
barrier
mucos
vaccin
deliveri
system
must
overcom
deliv
antigen
packag
host
cell
elicit
consist
protect
immun
respons
anatom
featur
upper
respiratori
tract
affect
deliveri
medic
particl
first
filter
hair
nostril
whose
surfac
cover
keratin
stratifi
squamou
epithelia
next
particl
must
travers
extern
nasal
valv
slitlik
passag
limit
airflow
nostril
intern
nasal
airway
djupesland
colleagu
estim
larg
highspe
droplet
averag
tradit
nasal
spray
reach
beyond
extern
nasal
valv
almost
larg
highspe
particl
transit
nasal
valv
deposit
intern
nasal
airway
averag
approxim
cm
surfac
area
cover
columnar
epithelia
ciliat
intern
nasal
airway
particl
deposit
nasal
mucosa
join
flow
mucu
swept
ciliat
epithelia
toward
pharynx
swallow
immun
surveil
antigen
flow
mucu
begin
taken
epitheli
cell
intraepitheli
dendrit
cell
surfac
macrophag
cell
see
fig
cine
might
pose
increas
risk
immunocompromis
person
administ
mucos
liveattenu
vaccin
revert
virul
genotyp
advers
affect
vaccine
spread
contact
commun
nasal
vaccin
anoth
risk
vaccin
antigen
live
inactiv
adjuv
excipi
might
affect
nearbi
cranial
nerv
travel
along
olfactori
nerv
cribriform
plate
brain
result
advers
nervou
system
effect
vaccin
target
lower
airway
may
induc
exacerb
bronchospasm
pulmonari
inflamm
life
threaten
anoth
risk
crosscontamin
respiratori
pathogen
one
patient
may
contamin
respiratori
immun
devic
spread
subsequ
patient
also
vaccin
aerosol
may
spread
beyond
intend
recipi
affect
person
vicin
mani
challeng
new
deliveri
technolog
achiev
mucos
immun
requir
rout
becom
practic
accept
young
field
publish
research
deliveri
system
anim
human
limit
report
anim
studi
deliveri
system
mention
system
design
human
respiratori
system
test
difficult
imposs
anim
model
final
perhap
signific
challeng
implement
novel
vaccin
deliveri
system
routin
immun
practic
regulatori
requir
need
ensur
system
safe
effect
requir
studi
clinic
trial
extrem
expens
vaccin
manufactur
typic
reluct
assum
cost
risk
relicens
exist
product
alreadi
deliv
profit
unless
potenti
benefit
market
advantag
signific
best
opportun
bring
altern
deliveri
routin
practic
may
use
new
deliveri
systemsfrom
startfor
new
vaccin
earli
develop
licensur
process
oral
ingest
intestin
deliveri
sever
human
vaccin
licens
use
success
deliveri
ingest
includ
polio
cholera
rotaviru
typhoid
adenoviru
see
chapter
opv
prototyp
mucos
vaccin
demonstr
key
advantag
challeng
mucos
vaccin
eas
deliveri
opv
drop
enabl
minim
train
volunt
distribut
housetohous
campaign
essenti
current
success
global
polio
erad
effort
opv
live
attenu
vaccin
success
mucos
vaccin
date
vaccin
result
increas
mucos
immun
particularli
intestin
evidenc
increas
secretori
iga
decreas
shed
vaccin
polioviru
subsequ
challeng
compar
ipv
given
inject
see
chapter
howev
even
minor
shed
vaccin
viru
result
transmiss
vaccin
viru
other
especi
concern
vaccin
viru
potenti
revers
virul
result
vaccineassoci
paralyt
poliomyel
vaccine
contact
even
sustain
outbreak
circul
vaccinederiv
poliovirus
anoth
concern
regard
mucos
vaccin
deliveri
demonstr
opv
inconsist
immun
respons
across
differ
popul
opv
produc
immunogen
respons
less
consist
children
develop
countri
children
industri
countri
may
caus
differ
intestin
microbiota
see
chapter
intestin
deliveri
oral
ingest
simpl
especi
liquid
opv
drop
littl
enter
tract
laiv
respiratorydeliv
vaccin
use
howev
multipl
clinic
trial
assess
vaccin
deliveri
respiratori
tract
mani
technolog
develop
mucos
vaccin
target
oral
respiratori
rout
major
focu
section
although
vagin
rectal
vaccin
may
effect
could
limit
accept
social
cultur
practic
reason
first
challeng
mucos
immun
determin
appropri
target
tissu
optim
target
tissu
fulli
understood
may
vari
differ
vaccin
oral
respiratori
vaccin
strategi
two
discret
target
area
vaccin
via
oral
rout
may
target
oral
mucosa
intestin
respiratori
vaccin
may
target
upper
respiratori
tract
nasal
passag
pharynx
larynx
lower
tract
trachea
bronchi
bronchiol
lung
nasal
oral
mucos
deliveri
pharyng
tonsil
like
target
tissu
respiratori
vaccin
may
requir
deposit
lower
airway
uptak
alveolar
macrophag
dendrit
cell
lower
airway
deposit
achiev
oral
nasal
inhal
scientif
method
evalu
compar
differ
target
tissu
yet
well
develop
second
challeng
select
anim
model
extrapol
result
human
mucos
vaccin
deliveri
interspeci
differ
immunolog
tissu
limit
interpret
anim
targettissu
research
result
human
moreov
size
anatomi
common
research
anim
differ
greatli
human
exampl
small
anim
rodent
nose
drop
may
deposit
entir
respiratori
tract
would
case
human
balmelli
colleagu
estim
vaccin
given
mice
drop
deposit
lung
mani
virus
bacteria
infect
human
grow
well
anim
model
exampl
speciesspecif
differ
distribut
sialic
acid
receptor
cell
surfac
crucial
factor
tissu
host
specif
influenza
virus
limit
number
anim
model
suitabl
influenza
research
speciesspecif
differ
make
difficult
use
anim
studi
live
attenu
vaccin
vaccin
vector
difficult
challeng
anim
assess
protect
imped
develop
safe
effect
mucos
vaccin
human
third
hurdl
mucos
immun
assur
deliveri
accur
dose
target
tissu
mass
volum
antigen
deliv
depend
mani
factor
intestin
deliveri
gastric
acid
may
destroy
much
antigen
dose
respiratori
deliveri
variabl
perform
deliveri
devic
techniqu
vaccin
differ
anatomi
physiolog
person
vaccin
affect
dose
deliv
fortun
mani
vaccin
wide
margin
dosag
necessari
induc
protect
dosag
risk
advers
event
increas
fourth
challeng
lack
accept
correl
protect
mucos
immun
mani
diseas
laboratori
assay
wellestablish
criteria
system
immunitysuch
antibodi
titer
certain
cutoffsthat
serv
mani
year
predict
protect
diseas
absenc
accept
serolog
cellular
correl
protect
induc
mucos
vaccin
clinic
trial
must
use
specif
diseaseprevent
end
point
make
studi
requir
licensur
much
larger
expens
sever
immun
safeti
concern
repres
challeng
mucos
vaccin
live
viru
bacteri
vaction
major
focu
publish
clinic
trial
oral
mucos
vaccin
clinic
data
tradit
prophylact
vaccin
deliv
via
sl
buccal
rout
although
studi
regist
clinicaltrialsgov
influenza
cholera
hpv
preclin
studi
sl
vaccin
demonstr
immunogen
mice
use
viral
vector
adenovirusbas
vaccin
bacteri
vector
bacillu
subtili
exampl
sl
immun
mice
recombin
adenovirusbas
vaccin
express
influenza
viru
hemagglutinin
induc
signific
level
sustain
hemagglutininspecif
mucos
iga
igg
provid
complet
protect
challeng
lethal
dose
homolog
viru
despit
potenti
benefit
oral
mucos
immun
signific
challeng
delay
progress
toward
commerci
avail
prophylact
vaccin
first
antigen
present
oral
mucosa
may
result
immun
toler
evidenc
success
sl
immunotherapi
product
design
induc
toler
produc
desir
protect
immun
respons
may
requir
manipul
antigen
formul
dose
well
addit
adjuv
anoth
problem
rapid
flow
saliva
limit
resid
time
antigen
mouth
opportun
contact
apc
sever
format
design
adapt
oral
drug
deliveri
system
increas
oral
resid
time
preclin
test
vaccin
oral
deliveri
complic
extrem
small
oral
caviti
small
anim
model
deliveri
liquid
vaccin
mouth
mice
limit
altern
deliveri
format
extrem
difficult
use
also
unlik
human
rodent
keratin
epithelia
buccal
mucosa
limit
compar
antigen
uptak
overcom
inher
mucos
toler
antigen
varieti
mucos
adjuv
studi
exampl
mice
sublingu
immun
influenza
vaccin
hemagglutinin
split
vaccin
lipopolysaccharid
adjuv
demonstr
hemagglutininspecif
igg
system
iga
mucos
antibodi
respons
led
signific
increas
surviv
rate
lethal
influenza
viru
challeng
compar
sc
vaccin
two
mucos
potent
stimul
natur
killer
cell
cytosin
phosphat
guanineoligodeoxynucleotid
tolllik
agonisteffect
increas
serum
igg
vagin
iga
level
follow
sl
vaccin
mice
combin
significantli
improv
respons
serum
vagin
wash
collect
day
immun
signific
neutral
activ
simian
human
immunodefici
viru
enhanc
resid
time
oral
mucosa
thermorespons
gelwhich
chang
aqueou
solut
viscou
gel
upon
contact
mucosa
bodi
temperaturewa
combin
doubl
mutant
bacteri
heatlabil
toxin
sl
immun
mice
trival
ipv
gel
deliveri
system
produc
mucos
serum
antibodi
includ
iga
interest
sl
vaccin
acceler
significantli
pubm
search
sublingu
vaccin
return
publish
articl
sinc
compar
prior
progress
candid
oral
mucos
vaccin
clinic
trial
commerci
requir
signific
addit
research
increas
understand
pharmacokinet
pharmacodynam
well
immunolog
mechan
rout
deliveri
inher
mucos
toler
antigen
limit
oral
resid
time
develop
optim
deliveri
formul
predict
assay
mucos
immun
particularli
challeng
technolog
develop
requir
macrodeliveri
oral
vaccin
new
technolog
intestin
vaccin
focu
microdeliveri
system
review
separ
section
one
biggest
hurdl
consist
deliveri
vaccin
antigen
apc
intestin
tract
ensur
antigen
surviv
degrad
gastric
acid
like
wild
polioviru
opv
stabl
acid
environ
sever
hour
enter
vaccin
cholera
rotaviru
vaccin
deliv
buffer
solut
neutral
gastric
acid
typhoid
fever
vaccin
deliv
lyophil
powder
protect
enter
coat
capsul
howev
capsul
appropri
infant
vaccin
oral
mucos
vaccin
sublingu
buccal
deliveri
preclin
studi
conduct
explor
potenti
administ
vaccin
via
sublingu
sl
buccal
mucosa
rout
long
use
lowmolecularweight
drug
nitroglycerin
sl
tablet
sever
sl
immunotherapi
vaccin
market
europ
suppress
allerg
hypersensit
major
advantag
oral
mucos
immun
eas
administr
includ
potenti
selfadministr
probabl
induc
robust
mucos
immun
contrast
intestin
deliveri
oral
absorb
antigen
subject
degrad
gastric
acid
oral
caviti
line
stratifi
epithelium
like
skin
oral
epithelium
replet
langerhan
cell
princip
target
apc
oral
vaccin
oral
surfac
hard
palat
keratin
upper
layer
epithelia
buccal
sl
mucosa
nonkeratin
lack
keratin
increas
permeabl
potenti
transport
antigen
mucos
apc
without
disrupt
penetr
stratum
corneum
requir
cutan
vaccin
exampl
fig
demonstr
wildtyp
measl
viru
replic
oral
mucosa
howev
salivari
mucu
flow
rapidli
move
substanc
oral
surfac
toward
pharynx
swallow
digest
mani
salivari
compon
initi
process
digest
degrad
oral
caviti
organ
lymphoid
tissu
intestin
peyer
patch
howev
movement
antigen
across
pharyng
tonsil
may
play
role
induct
immun
respons
unlik
nasal
deliveri
oral
deliveri
potenti
expos
cribriform
plate
vaccin
shim
colleagu
report
sl
vaccin
recombin
replicationdefici
adenoviru
express
sarsassoci
coronaviru
antigen
induc
protect
immun
sarsassoci
coronaviru
compar
seen
vaccin
adenovir
dna
detect
olfactori
bulb
mice
vaccin
intranas
mice
vaccin
sublingu
addit
immunotherapi
vaccin
two
novel
sl
vaccin
commerci
avail
spain
prevent
recurr
infect
one
uromun
mixtur
inactiv
whole
bacteria
select
strain
common
caus
urinari
tract
infect
uti
vaccin
selfadminist
daili
sl
spray
maintain
tongu
period
minut
swallow
clinic
studi
patient
recurr
uti
subject
receiv
vaccin
daili
month
significantli
reduc
occurr
uti
compar
subject
receiv
standard
therapi
sulfamethoxazol
trimethoprim
period
month
reduc
incid
uti
persist
month
complet
vaccin
immunotherapi
allergi
patient
use
polyval
inactiv
bacteri
prepar
suppress
recurr
infeca
dri
particl
size
suitabl
upper
lower
respiratori
tract
deposit
first
formul
powder
requir
signific
extens
chang
manufactur
method
second
mani
potenti
dryformul
ingredi
extrem
hygroscop
becom
sticki
expos
humid
third
powder
deposit
respiratori
tract
must
suffici
hygroscop
dissolv
releas
vaccin
uptak
howev
challeng
met
dri
aerosol
sever
advantag
liquid
aerosol
dose
fill
inexpens
singleus
present
deliv
without
onsit
aqueou
reconstitut
secondari
packag
seal
dose
contain
imperm
overwrap
metal
foil
could
maintain
low
humid
prolong
potenc
increas
shelf
life
minim
energi
requir
powder
dispers
compar
liquid
droplet
gener
electromechan
devic
necessari
nasal
spray
vaccin
current
licens
use
unit
state
respiratori
deliveri
coldadapt
laiv
flumist
deliv
accuspray
syring
laiv
develop
test
licensur
review
detail
chapter
laiv
demonstr
sever
potenti
benefit
respiratori
deliveri
produc
mucos
system
immun
gener
found
provid
higher
protect
efficaci
inject
inactiv
vaccin
young
children
also
provid
heterotyp
immun
nonvaccin
strain
deliveri
laiv
may
reduc
risk
influenza
transmiss
reduc
respiratori
shed
among
immun
children
challeng
later
vaccin
viru
final
modest
coverag
laiv
among
schoolchildren
reduc
influenzarel
ill
rate
unvaccin
adult
commun
howev
despit
previou
posit
result
laiv
vaccin
effect
data
influenza
season
found
flumist
provid
protect
benefit
children
center
diseas
control
prevent
cdc
advisori
committe
immun
practic
recommend
flumist
use
unit
state
accuspray
devic
steril
singlepatientus
dispos
prefil
glass
syring
fix
nonremov
plastic
nozzl
fig
b
total
dose
ml
ml
spray
consecut
nostril
attach
plunger
stop
first
dose
allow
user
switch
nostril
flumist
vaccin
deliv
accuspray
highli
effect
popul
see
chapter
key
advantag
accuspray
deliveri
simpl
use
low
cost
capabl
dispos
without
need
use
sharp
contain
low
possibl
refil
reus
larg
particl
size
gener
sprayer
minim
deposit
lower
airway
reduc
risk
advers
pulmonari
event
limit
system
particl
size
emit
depend
speed
vaccin
depress
plunger
median
diamet
particl
rang
greater
plunger
speed
mm
per
second
less
speed
mm
per
second
greater
although
wide
variabl
might
theori
affect
effici
vaccin
deposit
laiv
accuspray
typic
produc
high
rate
protect
immun
current
dosag
laiv
develop
russia
use
countri
year
see
chapter
vaccin
lyophil
must
reconstitut
fill
syring
poc
dose
come
lindal
group
atom
tip
fit
syring
remov
reconstitut
needl
deliveri
nostril
dose
divid
provid
dose
nostril
must
drawn
background
earliest
known
rout
vaccin
insuffl
powder
scab
materi
smallpox
patient
reportedli
practic
china
earli
centuri
ad
howev
laiv
respiratori
vaccin
modern
use
see
chapter
contrast
respiratori
rout
use
deliv
wide
expand
varieti
pharmaceut
product
respiratori
drug
administr
typic
target
one
two
major
area
upper
airway
lower
airway
common
product
nasal
decongest
inhal
asthma
medic
intend
local
therapi
target
area
newer
product
inhal
insulin
target
deposit
alveoli
achiev
system
deliveri
first
inhal
insulin
exubera
commerci
failur
partli
cumbersom
deliveri
devic
howev
anoth
product
insulin
inhal
afrezza
approv
fda
afrezza
use
small
simpl
dri
powder
inhal
mannkind
dreamboat
effici
effect
deliveri
respiratori
target
tissu
determin
larg
aerodynam
size
speed
vaccin
particl
function
devic
engin
product
formul
devic
upper
respiratori
tract
drug
deliveri
includ
dropper
nasal
sprayer
nasal
nebul
dri
powder
inhal
design
test
vaccin
drug
devic
deliv
repetit
dose
singl
patient
contrast
vaccin
deliv
singl
dose
multipl
patient
rais
issu
devic
crosscontamin
although
unitdos
dispos
devic
dispos
compon
could
solv
problem
must
inexpens
costeffect
mani
drugdeliveri
devic
design
selfadministr
howev
requir
level
patient
cooper
difficult
achiev
young
children
imposs
infant
mucos
vaccin
gener
optim
target
tissu
yet
understood
potenti
respiratori
vaccin
vari
differ
antigen
liquid
dropper
deliveri
perhap
simplest
devic
inexpens
prefil
singleus
dropper
commonli
use
administ
drug
upper
respiratori
tract
howev
drop
administ
intranas
tend
drip
nose
roll
back
pharynx
swallow
result
less
resid
time
nasal
passag
nasopharynx
less
contact
mucos
surfac
recumb
patient
posit
may
increas
nasal
resid
time
may
practic
poc
prefil
fillonsit
nasal
spray
devic
gener
smaller
particl
typic
rang
nasal
nebul
gener
even
smaller
particl
devic
may
increas
mucos
surfac
contact
resid
time
definit
studi
effect
immunogen
deposit
liquid
vaccin
lower
airway
requir
nebul
devic
gener
small
droplet
requir
pass
vocal
cord
reach
trachea
bronchi
alveoli
nebul
durabl
devic
requir
energi
sourc
gener
aerosol
devic
transit
aerosol
patient
mask
oral
prong
nasal
prong
singleus
dispos
compon
includ
patient
interfac
need
prevent
crosscontamin
dri
powder
aerosol
also
use
deposit
vaccin
upper
lower
respiratori
tract
liquid
deliveri
advantag
standard
format
current
licens
aerosol
vaccin
liquid
present
gener
spray
aerosol
exist
liquid
vaccin
formul
could
acceler
respiratori
vaccin
research
contrast
number
obstacl
must
overcom
produc
vaccin
vaxin
singleus
devic
consist
atom
spray
tip
compat
standard
luer
lock
fillonsit
syring
see
fig
dose
divid
attach
syring
plunger
separ
dose
deliveri
ml
per
nostril
one
advantag
vaxin
conic
tip
fit
nostril
size
limit
depth
separ
reattach
fill
needl
potenti
reus
devic
crosscontamin
risk
biodiem
commerci
right
russian
laiv
outsid
russia
licens
technolog
serum
institut
india
ltd
serum
institut
india
nasovac
vaccin
current
deliv
teleflex
prefil
liquid
vaccin
store
refriger
singl
patient
use
total
volum
ml
dose
separ
interrupt
deliveri
ml
remov
allow
remain
ml
administ
opposit
nostril
c
teleflex
vaxinin
nasal
spray
devic
current
use
deliv
serum
institut
india
ltd
nasovac
influenza
vaccin
conic
spray
tip
attach
syring
luer
fit
sagitt
computerassist
imag
illustr
intranas
deliveri
optinos
deliveri
devic
optinos
inc
e
dolphin
sideactiv
nasal
spray
dispos
unitspray
devic
design
deliv
product
two
spray
f
investig
aerovax
prototyp
crear
inc
use
batterypow
piezoelectr
energi
drive
aerosol
dispos
drug
cartridg
via
microperfor
mesh
plate
dispos
patient
interfac
nasal
prong
patient
nostril
oral
prong
mask
shown
droplet
diamet
tailor
upper
lower
airway
deliveri
respect
g
bespak
unidos
dp
dri
powder
prefil
unitdos
devic
deliv
medic
requir
predefin
amount
pressur
appli
plunger
devic
oper
thu
ensur
proper
dispers
h
investig
solov
becton
dickinson
co
dri
powder
inhal
prototyp
adapt
intranas
pulmonari
format
solov
small
cylindr
plastic
capsul
open
end
one
end
luer
fit
attach
standard
syring
provid
air
flow
end
patient
interfac
either
nasal
prong
snapfit
adapt
mate
mask
reservoir
capsul
contain
powder
dose
two
burstabl
plastic
membran
ruptur
airflow
provid
syring
plume
powder
upon
releas
solov
open
air
visual
purpos
investig
nasal
dri
powder
inhal
develop
cdc
crear
inc
prefil
cup
shown
right
thumb
forefing
contain
powder
vaccin
open
attach
devic
breath
patient
blow
devic
tube
carri
dri
powder
nose
dispers
patient
exhal
limit
pulmonari
deposit
posterior
nasal
space
plastic
face
phantom
model
airway
child
cfdrc
inc
j
medial
section
right
intern
nasal
airway
plastic
phantom
model
shown
describ
extern
nare
face
shown
right
proxim
nasal
valv
pharynx
shown
left
distal
nasopharyng
open
redpig
powder
indic
deposit
pattern
investig
nasal
dri
powder
inhal
shown
ab
fig
live
attenu
measl
vaccin
deliv
intranas
macaqu
solov
provid
immun
respons
equival
sc
inject
includ
protect
viru
challeng
anthrax
vaccin
rout
solov
provid
complet
protect
inhal
challeng
roughli
time
median
lethal
dose
rabbit
provid
better
stabil
liquid
formul
solov
deliveri
whole
inactiv
influenza
viru
product
rat
elicit
high
titer
nasal
antiinfluenza
iga
well
serum
antibodi
titer
equival
obtain
inject
vaccin
loss
potenc
found
store
rel
humid
week
rel
humid
week
investig
nasal
powder
deliveri
devic
develop
crear
inc
oper
patient
exhal
mouth
blow
powder
nose
simultan
gener
air
flow
limit
entri
lower
respiratori
tract
threedimension
plastic
model
develop
computer
tomographi
airway
anatomi
children
age
year
age
devic
consist
deliv
signific
fraction
fluorescein
powder
dose
target
airway
see
fig
j
increas
nasal
resid
time
dri
powder
formul
gelvac
develop
inert
situ
gell
polysaccharid
vaccin
gelvac
norwalkviru
vlp
induc
system
mucos
antibodi
titer
rat
guinea
pig
equal
greater
achiev
liquid
vlp
plu
adjuv
gelvac
powder
vaccin
administ
use
laboratoryconstruct
deliveri
devic
use
syring
provid
airflow
modifi
pipett
tip
serv
nasal
prong
although
mani
dri
powder
liquidspray
nasal
devic
use
drug
deliveri
human
test
vaccin
studi
anim
difficult
imposs
nostril
size
lower
airway
vaccin
deposit
vast
alveolar
surfac
area
abund
apc
make
lung
attract
target
vaccin
deliveri
howev
inflammatori
advers
reaction
vital
organ
could
grave
consequ
high
degre
caution
requir
signific
develop
insert
provid
vaccin
physic
guidanc
devic
placement
devic
potenti
reusabl
teleflex
offer
option
autodis
syring
automat
disabl
syring
vaxin
drug
deliv
inactiv
virosomalsubunit
influenza
vaccin
nasalflu
berna
biotech
licens
switzerland
administr
nasal
spray
nasalflu
contain
e
coli
heatlabil
toxin
mucos
adjuv
vaccin
withdrawn
market
increas
incid
temporari
paralysi
seventh
cranial
nerv
bell
palsi
consid
relat
heatlabil
toxin
adjuv
multipl
clinic
trial
conduct
laiv
addit
licens
vaccin
clinic
trial
type
influenza
vaccinesinclud
inactiv
virosom
live
replicationdefici
proteasom
vaccinesalso
demonstr
promis
immun
respons
studi
use
standard
nasal
spray
describ
deliveri
method
one
studi
use
novel
breathactu
nasal
spray
devic
optimist
deliv
liquid
dri
powder
aerosol
oral
exhal
method
rais
soft
palat
close
connect
nose
throat
pulmonari
deposit
avoid
deliveri
posterior
nasal
segment
increas
see
fig
inactiv
influenza
vaccin
selfadminist
use
optimist
result
signific
increas
virusspecif
iga
nasal
secret
well
protect
level
virusspecif
serum
antibodi
two
dose
subject
vaccin
clinic
trial
demonstr
encourag
immun
respons
includ
live
attenu
respiratori
syncyti
viru
parainfluenza
bordetella
pertussi
vaccin
norwalk
viru
vlp
vaccin
hepat
b
vaccin
exampl
live
attenu
respiratori
syncyti
viru
vaccin
administ
drop
seroneg
infant
month
age
produc
function
immun
respons
subject
riddl
colleagu
report
shigella
flexneri
subunit
vaccin
safe
well
toler
produc
robust
level
antigenspecif
intestin
iga
administ
dolphin
spray
devic
see
fig
nasal
drop
multipl
clinic
trial
almost
preclin
studi
vaccin
conduct
nasal
drop
unfortun
dropper
devic
deliveri
method
often
describ
sever
studi
compar
laiv
deliveri
nasal
spray
liquid
dropper
deliveri
multicent
studi
children
month
age
king
colleagu
detect
statist
signific
differ
reactogen
immunogen
subject
receiv
laiv
drop
spray
four
differ
dose
anoth
studi
four
weekli
dose
inactiv
influenza
vaccin
given
drop
per
nostril
vaccine
supin
posit
tilt
couch
head
lower
minut
order
retain
vaccin
within
nasopharyng
area
vaccin
drop
produc
hemagglutinationinhibit
antibodi
titer
consid
protect
subject
nasal
nebul
sever
nebul
capac
deliv
aerosol
live
attenu
measl
vaccin
administ
via
nasal
prong
aerovax
nebul
see
fig
crear
inc
shown
safe
immunogen
macaqu
aerovax
deliveri
laiv
ferret
elicit
high
level
serumneutr
antibodi
protect
homolog
viru
challeng
convent
median
tissu
cultur
infect
dose
tcid
significantli
reduc
tcid
dosag
provid
signific
level
subtypespecif
crossprotect
intranas
dri
powder
multipl
clinic
trial
powder
vaccin
includ
chitosan
mucoadhes
american
red
cross
initi
measl
aerosol
project
goal
licensur
least
one
live
attenu
measl
vaccin
associ
aerosol
deliveri
system
develop
world
project
document
immunogen
safeti
ie
lack
local
system
toxic
anim
studi
three
exist
therapeut
nebul
use
phase
clinic
trial
aeroeclips
compair
aeroneb
measl
vaccin
deliveri
three
devic
deliv
subject
india
report
safe
well
toler
immunogen
modifi
version
batteryoper
aeroneb
vibrat
mesh
nebul
aerogen
devic
see
fig
select
use
phase
iiiii
pivot
trial
initi
measl
aerosol
project
studi
random
openlabel
activecontrol
noninferior
trial
measl
vaccin
unvaccin
healthi
infant
month
age
aerosol
deliveri
vaccin
reconstitut
diluent
administ
singl
dose
nebul
second
singleus
nonvent
face
mask
nebul
gener
aerosol
median
diamet
fullanalysi
set
children
aerosol
group
children
sc
group
seroposit
day
differ
percentag
point
confid
interv
fail
meet
predetermin
noninferior
margin
seriou
advers
event
attribut
measl
vaccin
adverseev
profil
similar
two
group
recent
clinic
studi
rubella
mump
vaccin
use
combin
measl
vaccin
aerosol
deliveri
bennett
colleagu
found
aerosol
vaccin
preschool
children
combin
mmr
vaccin
produc
antibodi
respons
antigen
equival
produc
inject
cowork
found
aerosol
measlesrubella
combin
vaccin
schoolag
children
produc
level
measl
rubella
antibodi
equival
higher
level
seen
sc
inject
fewer
advers
event
report
aerosol
group
diazortega
colleagu
found
mmr
vaccin
aerosol
colleg
student
produc
immun
respons
similar
produc
inject
seroposit
retain
vaccine
year
vaccin
clinic
trial
pulmonari
aerosol
deliveri
vaccin
report
small
phase
doubleblind
trial
aerosol
deliveri
compar
id
deliveri
modifi
vaccinia
ankaravector
vaccin
deliv
mycobacterium
tuberculosi
antigen
aerosol
administ
liquid
dose
use
omron
microair
vibrat
mesh
nebul
administr
rout
well
toler
advers
event
immunogen
system
respons
similar
across
group
cell
detect
bronchoalveolar
lavag
cell
group
respons
higher
aerosol
group
id
group
pulmonari
dri
powder
measl
vaccin
pathfind
applic
respiratori
dri
powder
vaccin
earli
formul
fine
mill
retain
adequ
potenc
immun
respons
poor
deliv
respiratori
tract
macaqu
aktivdri
award
grand
challeng
global
health
grant
measl
vaccin
dri
powder
mvdp
project
project
goal
refin
dri
powder
measl
vaccin
formul
establish
product
capac
serum
institut
india
complet
preclin
phase
clinic
test
novel
spraydri
system
use
manufactur
inhal
mvdp
minim
potenc
loss
dri
process
pulmonari
drug
deliveri
achiev
might
adapt
vaccin
deliveri
pulmonari
liquid
aerosol
measl
vaccin
wide
studi
vaccin
target
pulmonari
deliveri
earli
clinic
studi
drop
spray
deliv
conjunctiva
oral
nasal
mucosa
produc
inconsist
immun
respons
prompt
research
consid
aerosol
pulmonari
deliveri
albert
sabin
earli
pioneer
advoc
deliveri
method
signific
bodi
clinic
research
aerosol
measl
publish
summar
review
articl
metaanalys
primari
find
deliveri
nebulizergener
smallparticl
liquid
aerosol
via
pulmonari
inhal
children
month
age
older
typic
produc
immun
respons
high
proport
subject
usual
equival
greater
respons
inject
vaccin
exampl
dilraj
colleagu
found
schoolchildren
receiv
aerosol
measl
vaccin
antibodi
titer
greater
iuml
year
vaccin
respect
compar
among
receiv
inject
vaccin
contrast
gener
lower
immun
respons
found
aerosol
rout
compar
parenter
inject
among
children
younger
month
exampl
wongchew
cowork
found
vaccin
infant
inject
induc
immun
aerosol
rout
respect
one
hypothesi
low
respiratori
volum
infant
result
inhal
dose
aerosol
vaccin
small
period
followup
studi
wongchew
colleagu
demonstr
increas
exposur
time
aerosol
measl
vaccin
elicit
immun
respons
compar
seen
sc
rout
infant
regard
vaccin
safeti
review
metaanalys
note
sever
advers
event
report
aerosol
measl
vaccin
studi
rate
minor
advers
event
report
typic
less
vaccin
inject
experi
mass
campaign
similar
de
castro
colleagu
report
seriou
advers
event
among
million
children
mexico
vaccin
aerosol
jet
nebul
system
known
classic
mexican
devic
see
fig
b
use
mani
measl
aerosol
clinic
studi
mass
campaign
mexico
system
consist
generalus
nonmedicalgrad
compressor
deliv
air
jet
nebul
hold
vaccin
crush
ice
maintain
potenc
vaccin
session
vaccin
aerosol
deliv
reusabl
plastic
tube
singleus
dispos
paper
cone
modifi
drink
cup
held
close
patient
face
second
typic
aerosol
dose
volum
roughli
ml
mass
median
aerosol
diamet
droplet
studi
assess
distribut
viabl
vaccin
viru
across
rang
droplet
size
emit
classic
mexican
devic
coat
cowork
estim
infect
viral
particl
contain
droplet
diamet
less
droplet
greater
vaccin
deliveri
lower
respiratori
tract
possibl
identifi
target
tissu
essenti
product
immun
respons
although
classic
mexican
devic
demonstr
level
safeti
immunogen
heavi
cumbersom
noisi
requir
outlet
main
electr
crush
ice
thu
practic
routin
vaccin
encourag
result
earli
measl
aerosol
vaccin
trial
partnership
cdc
trial
b
nonmed
electr
compressor
shown
deliv
roughli
l
air
per
minut
pressur
psi
kpa
jet
nebul
kept
crush
ice
maintain
vaccin
potenc
vaccin
aerosol
roughli
cm
particl
averag
diamet
deliv
dispos
paper
cone
held
close
patient
face
second
c
aerogen
aeroneb
go
batteri
power
vibrat
mesh
nebul
use
basi
measl
aerosol
project
clinic
trial
devic
cap
thumb
finger
remov
fill
upper
chamber
microperfor
vibrat
mesh
disk
base
chamber
aerosol
dose
lower
chamber
patient
inhal
aerosol
mouthpiec
attach
mask
shown
cord
connect
batteri
control
pack
investig
solov
dri
powder
inhal
prototyp
pulmonari
deliveri
format
becton
dickinson
co
air
empti
syring
ruptur
membran
vaccin
contain
releas
cardstock
spacer
plume
dri
powder
patient
inhal
cardstock
spacer
directli
via
mask
vaccin
contain
capsul
spacer
mask
singleus
dispos
e
f
investig
puffhal
dri
powder
inhal
aktivdri
llc
e
air
squeez
bulb
loft
vaccin
powder
dispers
reservoir
pressur
threshold
burst
valv
exceed
f
patient
inhal
singleuseonli
reservoir
puffhal
detach
devic
either
directli
shown
via
dispos
mask
shown
g
investig
twincer
singleus
dispos
dri
powder
inhal
pulmonari
deliveri
univers
groningen
drug
formul
store
snaptogeth
plate
devic
aluminum
blister
maxim
moistur
protect
powder
becom
avail
inhal
upon
pull
foil
cover
protrud
rear
inhal
shown
ab
recombin
virus
bacteria
act
vaccin
vector
incorpor
gene
express
heterolog
antigen
recombin
vector
also
express
adjuv
replic
system
advantag
similar
convent
live
attenu
viru
vaccin
deliv
genet
code
vaccin
antigen
adjuv
host
cell
replic
cell
manufactur
vaccin
compon
activ
immun
system
virus
bacteria
use
vaccin
vector
ideal
low
pathogen
potenti
even
immunocompromis
peopl
capac
incorpor
necessari
foreign
gene
desir
antigen
promot
adjuv
vector
bacteria
advantag
virus
higher
capac
insert
heterolog
gene
express
antigen
adjuv
plasmid
dna
vaccin
one
caveat
use
vector
vaccin
preexist
immun
vector
may
reduc
vaccin
effect
dna
vaccin
involv
deliveri
eponym
plasmid
directli
host
cell
express
desir
antigen
adjuv
nake
dna
lack
cellular
entri
mechan
critic
hurdl
get
dna
cell
without
degrad
live
attenu
bacteria
especi
salmonella
shigella
vector
produc
dna
vaccin
virosom
liposom
microparticl
also
use
deliv
dna
vaccin
nonrepl
vaccin
deliveri
system
synthet
construct
includ
liposom
vlp
virosom
immun
stimul
complex
microparticl
nanoparticl
nonrepl
deliveri
system
mimic
live
virus
way
appear
immun
system
enhanc
antigen
deliveri
may
also
carri
adjuv
particl
size
virus
allow
similar
uptak
apc
mani
includ
lipid
compon
increas
cell
membran
permeabl
may
contain
unrel
viral
bacteri
protein
activ
immun
system
one
novel
method
deliv
antigen
recipi
apc
extract
apc
peripher
blood
draw
exampl
cultur
antigen
administ
autolog
antigenladen
apc
via
intraven
im
sc
inject
autolog
dendrit
cellbas
vaccin
develop
cur
cancer
vaccin
adjuv
nonrepl
antigen
typic
poorli
immunogen
may
requir
adjuv
stimul
appropri
immun
respons
one
mechan
adjuv
action
provid
warn
label
impli
antigen
packag
potenti
pathogen
alert
cell
induc
innat
immun
adjuv
studi
purpos
includ
pathogen
compon
bacteri
toxin
deriv
bacteri
compon
bacteri
dna
motif
adjuv
includ
cytokin
chemokin
cell
produc
induc
innat
immun
anoth
adjuv
mechan
increas
resid
time
antigen
target
tissu
prolong
opportun
antigen
packag
taken
apc
aluminum
adjuv
provid
depot
effect
mani
inactiv
vaccin
deliv
intramuscularli
subcutan
mucos
deliveri
nanoemuls
natur
polym
chitosan
mucoadhes
properti
delay
mucos
antigen
clearanc
pulmonari
deliveri
vaccin
powder
solov
devic
see
fig
aktivdri
develop
puffhal
devic
see
fig
f
demonstr
robust
immun
respons
macaqu
includ
serum
antibodi
tcell
respons
protect
viral
challeng
devic
deliv
aerosol
reservoir
mask
deliveri
toxicolog
studi
found
testarticlerel
effect
delay
onset
toxic
inhal
spragu
dawley
rat
effect
mortal
clinic
observ
respiratori
function
clinic
patholog
histopatholog
rhesu
macaqu
phase
mvdp
safeti
trial
vaccin
conduct
adult
india
subject
randomli
assign
ratio
receiv
mvdp
via
puffhal
devic
solov
devic
licens
sc
measl
vaccin
advers
event
report
mvdp
produc
serolog
respons
similar
sc
vaccin
vaccin
develop
pulmonari
powder
deliveri
includ
influenza
tuberculosi
hepat
b
exampl
pulmonari
powder
formul
produc
sfd
influenza
subunit
viral
antigen
inulin
stabil
induc
humor
igg
cellmedi
mucos
iga
igg
immun
respons
balbc
mice
test
separ
novel
dri
powder
inhal
singleus
dispos
twincer
see
fig
inulinbas
dri
powder
subunit
influenza
vaccin
dispers
aerodynam
particl
size
distribut
suitabl
pulmonari
administr
vaccin
deliv
appropri
target
tissu
suffici
quantiti
antigen
must
gain
access
apc
activ
immun
system
microdeliveri
vehicl
vector
use
purpos
includ
live
attenu
virus
includ
act
vector
exogen
antigen
live
attenu
bacteria
includ
vector
commens
bacteri
vector
virosom
vlp
liposom
lipopeptid
immun
stimul
complex
microparticl
nanoparticl
dendrit
cell
vaccin
microdeliveri
system
describ
detail
chapter
includ
abbrevi
descript
system
complet
discuss
immun
antigen
packag
deliveri
system
virus
bacteria
prototyp
antigen
deliveri
vehicl
sever
reason
packag
size
optim
cellular
uptak
b
viral
surfac
coat
molecul
attach
cellular
receptor
process
ring
packag
deliveri
bell
ie
cell
recogn
potenti
pathogen
activ
innat
immun
increas
cellular
uptak
c
insid
virus
command
cellular
system
replic
multipli
exponenti
vaccin
antigen
encod
bacteria
selfrepl
tissu
insid
cell
multipli
vaccin
antigen
avail
apc
live
attenu
strain
pathogen
virus
bacteria
among
common
type
vaccin
use
everi
deliveri
rout
major
risk
attenu
pathogen
vaccin
potenti
pathogen
effect
may
occur
immunocompromis
person
follow
viral
revers
virul
form
exposur
unintend
tissu
neurotox
follow
exposur
via
olfactori
rout
futur
vaccin
technolog
determin
strateg
next
step
guid
enabl
develop
introduct
uptak
new
technolog
potenti
posit
public
health
impact
integr
product
would
elimin
need
reconstitut
provid
improv
thermost
offer
needlefre
deliveri
highlight
prioriti
technolog
develop
area
mark
papania
coinventor
correspond
financi
interest
aerovax
cdc
crear
inc
dri
powder
inhal
cdc
crear
inc
devic
illustr
fig
refer
chapter
avail
expertconsultcom
new
technolog
deliv
antigen
packag
potenti
overcom
logist
hurdl
imped
deliveri
vaccin
popul
need
practic
ideal
vaccin
would
safe
effect
inexpens
would
characterist
packag
singleunit
dose
minim
wastag
miss
opportun
vaccin
thermost
ambient
temperatur
make
vaccin
easi
store
ship
even
via
routin
deliveri
system
postal
servic
avail
prefil
dose
format
obviat
onsit
reconstitut
fill
simpl
administ
selfadminist
reduc
depend
highli
skill
healthcar
worker
needlefre
reduc
risk
sharp
injuri
needl
reus
burden
sharp
wast
dispos
combin
new
technolog
stabil
packag
vaccin
new
vaccin
administr
technolog
new
molecular
antigen
deliveri
system
adjuv
could
yield
practic
ideal
vaccin
next
decad
howev
promis
technolog
describ
chapter
face
daunt
obstacl
bridg
gap
success
proof
principl
expens
complic
seri
clinic
trial
relat
studi
regulatori
step
ensur
novel
system
safe
effect
achiev
licensur
gener
avail
initi
cost
develop
licens
suppli
practic
ideal
vaccin
high
encourag
financ
clear
demanda
willing
paymust
express
advanc
key
stakehold
includ
public
health
immun
program
polici
maker
vaccin
purchas
independ
philanthrop
entiti
creat
demand
stakehold
must
awar
potenti
new
technolog
convinc
cost
develop
practic
ideal
vaccin
outweigh
benefit
reduc
longterm
cost
current
ineffici
immun
system
februari
held
meet
nextgener
vaccin
deliveri
technolog
conduct
rapid
review
exist
futur
technolog
provid
vision
